

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 221/20, A61K 31/435, C07D 498/10, 471/10, 401/06, 263/52, A61K 31/42 // (C07D 498/10, 263:00, 221:00) (C07D 498/10, 261:00, 221:00) (C07D 498/10, 265:00, 221:00) (C07D 471/10, 235:00, 221:00) (C07D 471/10, 221:00, 221:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/11940 (43) International Publication Date: 3 April 1997 (03.04.97)</p>
<p>(21) International Application Number: PCT/US96/15703 (22) International Filing Date: 27 September 1996 (27.09.96) (30) Priority Data: 60/004,557 29 September 1995 (29.09.95) US (71) Applicants (for all designated States except US): ELI LILLY AND COMPANY [US/US]; Lilly Corporate Center, Indianapolis, IN 46285 (US). COR THERAPEUTICS, INC. [US/US]; 256 East Grand Avenue, South San Francisco, CA 94080 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): FISHER, Matthew, J. [US/US]; 4106 Armon Court, Carmel, IN 46033 (US). JAKUBOWSKI, Joseph, A. [US/US]; 3740 Governors Road, Indianapolis, IN 46208 (US). MASTERS, John, J. [US/US]; 8338 Crystal Pointe Lane, Indianapolis, IN 46236 (US). MULLANEY, Jeffrey, T. [US/US]; 6153 Welker Drive, Indianapolis, IN 46236 (US). PAAL, Michael</p>		<p>[DE/DE]; Hummelsbütteler Kirchenweg 11, D-22335 Hamburg (DE). RÜHTER, Gerd [DE/DE]; Vierzigstücken 53 a, D-21129 Hamburg (DE). RUTERBORIES, Kenneth, J. [US/US]; 6747 Bluffridge Court, Indianapolis, IN 46278 (US). SCARBOROUGH, Robert, M. [US/US]; 2544 Belmont Canyon Road, Belmont, CA 94002 (US). SCHOTTEN, Theo [DE/DE]; Hintern Bach 34, D-21444 Vierhöfen (DE). STENZEL, Wolfgang [DE/DE]; Lerchenweg 8, D-21465 Reinbek (DE). (74) Agents: LEEDS, James, P. et al.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285 (US). (81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>
<p>(54) Title: SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT PLATELET AGGREGATION (57) Abstract <p>This invention relates to certain spirocyclic compounds substituted with both basic and acidic functionality, which are useful in inhibition of platelet aggregation.</p></p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

SPIRO COMPOUNDS AS INHIBITORS OF FIBRINOGEN-DEPENDENT
PLATELET AGGREGATION

5

Field of the Invention

This invention relates to novel spiro compounds useful
as glycoprotein IIb/IIIa antagonists for the prevention of
10 thrombosis.

Background of the Invention

The most prevalent vascular disease states are
related to platelet dependent narrowing of the blood supply
15 such as atherosclerosis and arteriosclerosis, acute
myocardial infarction, chronic stable angina, unstable
angina, transient ischemic attacks and strokes, peripheral
vascular disease, arterial thrombosis, preeclampsia,
embolism, restenosis following angioplasty, carotid
20 endarterectomy, anastomosis of vascular grafts, and etc.
These conditions represent a variety of disorders thought to
be initiated by platelet activation on vessel walls.

Platelet adhesion and aggregation is believed to be
an important part of thrombus formation. This activity is
25 mediated by a number of platelet adhesive glycoproteins. The
binding sites for fibrinogen, fibronectin and other clotting
factors have been located on the platelet membrane
glycoprotein complex IIb/IIIa. When a platelet is activated
by an agonist such as thrombin the GPIIb/IIIa binding site
30 becomes available to fibrinogen, eventually resulting in
platelet aggregation and clot formation.


Heretofore it has been proposed to block these thrombus formation sites by the use of various therapeutic agents.

There is a need in the area of cardiovascular and cerebrovascular therapeutics for new agents which can be used in the prevention and treatment of thrombi.

It is a discovery of this invention that certain novel spiro compounds block the GPIIb/IIIa fibrinogen receptor, thereby inhibiting platelet aggregation and subsequent thrombus formation. Pharmaceutical formulations containing the spiro compounds of this invention inhibit aggregation and are useful for the prophylaxis and treatment of thrombogenic diseases, such as myocardial infarction, angina, stroke, peripheral arterial disease, disseminated intravascular coagulation and venous thrombosis.

Summary of the Invention

The present invention covers novel spiro compounds having a spiro nucleus formed from two fused rings, A and B, represented by the formula (I), as hereinafter defined, and all pharmaceutically-acceptable salts, solvates and prodrug derivatives thereof:



having substituents and subscripts; Q, -(L)-, A_i, p, R₁₀, m, n, R₀, B_j, q, and R₃, as hereinafter defined.

30 Another aspect of the invention is a pharmaceutical formulation containing a novel spiro compound of the invention.

Another aspect of the invention is a method of inhibiting platelet aggregation, inhibiting fibrinogen binding, or preventing thrombosis by administering to a mammal the novel spiro compounds of the invention.

5 Another aspect of this invention is a method of treating a human to alleviate the pathological effects of atherosclerosis and arteriosclerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes, peripheral vascular disease,
10 arterial thrombosis, preeclampsia, embolism, restenosis following angioplasty, carotid endarterectomy, and anastomosis of vascular grafts; wherein the method comprises administering to said human a therapeutically-effective amount of a novel spiro compound of this invention.

15

Detailed Description of the Invention

Definitions:

20 The term "spiro" refers to a compound consisting of two rings having only one carbon atom in common. Spiropentane is an exemplary compound having a spiro system. Spiro systems exclude other bicyclic compounds such as naphthalene which have two or more carbon atoms in common.

25 The term "alkyl" used herein refers to a monovalent straight or branched chain radical of from one to ten carbon atoms, including, but not limited to methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, n-hexyl, and the like.

30 The term "halosubstituted alkyl" as used herein refers to an alkyl group as just defined, substituted by one, two or three halogen atoms selected from fluorine, chlorine, bromine, and iodine. Examples of such groups include
chloromethyl, bromoethyl, trifluoromethyl, and the like.

35 The term "aryl" when used alone means a homocyclic aromatic radical whether or not fused. Preferred aryl groups

include phenyl, naphthyl, biphenyl, phenanthrenyl, naphthacenyl, and the like.

The term "substituted aryl" denotes an aryl group substituted with one, two, or three substituents chosen from
 5 halogen, hydroxy, protected hydroxy, cyano, nitro, C₁-C₁₀ alkyl, C₁-C₁₀ alkoxy, trifluoromethyl, amino, aminomethyl, and the like. Examples of such groups are 4-chlorophenyl, 2-methylphenyl, 3-methyl-4-hydroxyphenyl, and 3-ethoxyphenyl.


The term "arylalkyl" means one, two or three aryl
 10 groups having the number of carbon atoms designated, appended to an alkyl radical having the number of carbon atoms designated. A typical arylalkyl group is the benzyl group.

The term "alkenyl" as used herein refers to a monovalent straight or branched chain radical of from two to
 15 six carbon atoms containing a carbon double bond including, but not limited to, 1-propenyl, 2-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl and the like.

The term "alkylene" as used herein refers to a divalent straight or branched chain group of from one to ten
 20 carbon atoms, including but not limited to, -CH₂-, -(CH₂)₂-, -(CH₂)₃-, -CH(CH₃)-, -CH(C₂H₅)-, -CH(CH₃)CH₂-, and the like.


The term "alkenylene" as used herein refers to a divalent straight or branched chain group of from two to ten
 25 carbon atoms containing a carbon-carbon double bond, including but not limited to, -CH=CH-, -C(CH₃)=CH-, CH=CH-CH₂-, -CH=C(CH₃)-CH₂-, -CH₂CH(CH=CH₂)CH₂, and the like.

The term "alkynylene" as used herein refers to a divalent straight or branched chain group of from two to ten
 30 carbon atoms containing a carbon-carbon triple bond, including but not limited to,



and the like.

The term "amidino" refers to the radical having the structural formula;





5






The term "basic radical" refers to an organic radical which is a proton acceptor. Illustrative basic radicals are amino and amidino. Basic radicals may also be formed from a ring nitrogen.

10 The term "basic group" refers to an organic group containing one or more basic radicals. A basic group may comprise only an basic radical.


The term "acid radical" refers to an organic radical which is a proton donor. Illustrative acid radicals
15 include;



6



and.



5


The term "acidic group" is an organic group containing one or more acid radicals. An acidic group may comprise only an acid radical.

10 The term "non-interfering substituent" refers to an organic radical which does not significantly reduce the therapeutic effectiveness of a compound.

Compounds of the Invention:

This invention provides compounds of the general formula (I), or a pharmaceutically-acceptable salt, solvate or or prodrug thereof:

5



wherein;

the atoms A_i and B_j are independently selected from
 10 carbon, nitrogen, oxygen or sulfur, provided that at least
 one atom of A_i is carbon, and at least one atom B_j is carbon;

the rings of the spirobicycle formed by A_i and B_j ,
 respectively, may optionally be partly unsaturated;

p and q are independently numbers from 2 to 6;

15 m is a number from zero to p ;

R_{10} is the same or different and is a non-
 interfering substituent independently selected from hydrogen,
 alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl,
 aryl, arylalkyl, hydroxy, alkoxy, arylalkoxy, amino,
 20 substituted amino, carbamoyl, carboxy, acyl, cyano, halo,
 nitro, sulfo, =O, or =S, with the proviso that only one R_{10}
 may be =O or =S, if p is 2 or one or two R_{10} may be =O or =S,
 if p is a number from 3 to 6;

n is the number from zero to q ;

25 R_0 is the same or different and is a non-interfering
 substituent independently selected from hydrogen, alkyl,
 halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
 arylalkyl, hydroxy, alkoxy, arylalkoxy, amino, substituted
 amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, sulfo,
 30 =O, or =S, with the proviso that only one R_0 may be =O or =S,
 if q is 2 or one or two R_0 may be =O or =S, if q is a number
 from 3 to 6;


the linking group $-(L)-$ is a bond or a divalent substituted or unsubstituted chain of from 1 to 10 atoms selected from the group consisting of carbon, nitrogen, sulfur, and oxygen;

5 Q is a basic group containing one or more basic radicals; and

R_3 is an acidic group containing one or more acid radicals.


10 Compounds of the Invention with Preferred Spiro Nuclei:

A compound of formula (II), or a pharmaceutically-acceptable salt, solvate or prodrug thereof:




wherein Z is a spirocyclic nucleus selected from (A), (B), (C), or (D) below

20 Nucleus (A):





Nucleus (B):

25



Nucleus (C):

5 Nucleus (D):

wherein:

10 the group $Q-(L)_z-$ is bound to the nitrogen containing ring of nuclei (A), (B), (C), or (D) and the group R_3 is bound to the ring formed by the groups A_{41} , A_{42} , A_{43} , A_{51} , A_{52} , A_{53} , A_{54} , A_{61} , A_{62} , A_{63} , A_{64} , A_{65} , A_{71} , A_{72} , A_{73} , A_{74} , A_{75} , or A_{76} ; or

15 the group R_3 is bound to the nitrogen containing ring and the group $Q-(L)_z-$ is bound to the ring formed by the groups A_{41} , A_{42} , A_{43} , A_{51} , A_{52} , A_{53} , A_{54} , A_{61} , A_{62} , A_{63} , A_{64} , A_{65} , A_{71} , A_{72} , A_{73} , A_{74} , A_{75} , or A_{76} ;

20 r and s are independently a number from zero to 5 with the proviso that not both r or s are 0 and $(r + s)$ is not more than 6, and z is zero or one;

atoms A_{41} , A_{42} , A_{43} , A_{51} , A_{52} , A_{53} , A_{54} , A_{61} , A_{62} , A_{63} , A_{64} , A_{65} , A_{71} , A_{72} , A_{73} , A_{74} , A_{75} , or A_{76} are independently selected from carbon, nitrogen, oxygen or sulfur, provided
25 that at least one of said atoms is carbon;

the hydrogens of the nitrogen containing part of the spirocycle Z may be substituted by a number of m substituents R_{10} , wherein;

m is a number from zero to $(r + s)$; and

R_{10} is the same or different and is a non-interfering substituent independently selected from alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, arylalkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, sulfo, =O, or =S, with the proviso that only one or two R_{10} may be =O or =S;


n is a number from zero to 3 in Z of having nuclei (A), or a number from zero to 4 in Z having nuclei (B), a number from zero to 5 in Z having nuclei (C), or a number from zero to 6 in Z having nuclei (D);

R_0 is the same or different and is a non-interfering substituent independently selected from alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, arylalkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, sulfo, =O, or =S, with the proviso that only one or two R_0 may be =O or =S; and



Q , L , and R_3 are as defined previously for the formula I compounds.

Representative Spirocyclic Nuclei:

The spirocyclic compounds of the invention include spirocyclic nuclei selected from the group represented by the following structural formulae:










11



5

10

12




5











10

Representative oxo substituted Spirocyclic nuclei are as follows:

Oxo substituted spirocyclic compounds of the invention include spirocyclic nuclei selected from the group
5 represented by the following structural formulae:




14










5








10




Preferred spirocyclic nuclei include the following nuclei:








, or




where m is one or two.

A group of more preferred spirocyclic nuclei
5 includes the following groups:




where m is one or two.

A second group of more preferred nuclei include the following:





where m is one or two.

The most preferred spirocyclic nuclei include the following nuclei:



5



, or




where m is one or two.


10 The Basic Substituent Q:

The substituent Q of formulae (I) and (II) is a basic group. A basic group contains one or more basic radicals. Suitable basic radicals contain one or more nitrogen atoms and include amino, imino, amidino, hydroxyamidino, N-alkylamidines, N,N'-dialkylamidines, N-arylamidines, aminomethyleneamino, iminomethylamino, guanidino, aminoguanidino, alkylamino, dialkylamino, trialkylamino, alkylideneamino, pyrrolyl, imidazolyl, pyrazolyl, pyridyl, pyrazinyl, pyrimidinyl, indolizinyll, isoindolyl, 3H-indolyl, indolyl, 1H-indazolyl, purinyl, 4H-quinolizinyll, isoquinolyl, quinolyl, phthalazinyl, naphthyridinyl, quinoxalinyl, quinazolinyl, cinnolinyl,

- amide, thioamide, benzamidino, pteridinyl, 4aH-carbozoyl, carbozoyl, beta-carbolinyl, phenanthridinyl, acridinyl, pyrimidinyl, phenanthrolinyl, phenazinyl, phenarsazinyl, phenothiazinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, 5 pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, isoindolinyl, quinuclidinyl, morpholinyl, or any of the preceding substituted with amino, imino, amidino, hydroxyamidino, aminomethyleneamino, iminomethylamino, guanidino, alkylamino, dialkylamino, trialkylamino, 10 tetrahydroisoquinoline, dihydrosioindole, alkylideneamino groups or a group represented by the formula;




- 15 Preferred basic radicals are selected from amino, piperidyl, guanidino, hydroxyamidino, and amidino. The most preferred basic radicals are amidino, hydroxyamidino, and piperidyl represented by the formulae;



20

- The basic group and linker, $Q-(L)_z-$, may have the form of a basic radical pendant on a cyclic ring as shown in formula IV below. The D of Formula (IV) ring may also have 25 substituents R_{20} which are selected from chlorine, fluorine or non-interfering organic radicals. Fluorine is preferred as a substituent on the D ring. The R_{20} substituents may be t in number, where t is an integer from zero to the number of unsatisfied bonds in the D ring. The basic radical(s)


attaches to the D ring in the manner shown in formula (IV) below:




5

Suitable D rings are formed from a nucleus selected from the group consisting of; benzene, cycloheptadiene, cycloheptatriene, cycloheptane, cyclohexane, cyclohexene, cyclohexadiene, cycloheptene, cyclooctadiene, cyclooctane, cyclooctatetraene, cyclooctene, cyclopentane, cyclopentene, imidazole, isooxazole, morpholine, oxazole, piperazine, piperidine, pyrazine, pyrazole, pyridine, pyrimidine, pyrrole, pyrrolidine, pyrroline, tetrahydropyridine, tetrahydropyrimidine, 1H-tetrazole, thiazolidine, thiazole, thiopyran, 1,3,5-triazine, 1,2,3-triazole, 1,2,4-triazole, dihydrofuran, dihydropyran, dioxane, dioxepin, dioxolane, furan, oxocane, tetrahydrofuran, tetrahydropyran, thiophene, and tetrahydrothiophene.



20 An illustrative species of formula (IV) is the basic radical attached to a benzene ring as shown in formulae (V) and (VI) below:




and



The preferred basics groups include the following groups:



or




5 wherein R₂₀ is hydrogen or halogen.

The Acidic Substituent R₃


The substituent R₃ of formula (I) or (II) is an acidic group. An acidic group contains one or more acidic radicals. Suitable acidic radicals contain one or more proton donors, and include groups such as sulfonic acids, tetrazoles, phosphonic acids, carboxylic acids, and the like. The acidic radical may be bound to an aryl group, such as phenyl; or substituted phenyl, or bound to alkyl chains, such as methylene. These groups may also be bound to the spirocyclic nucleus through alkyl chains having heteroatoms, such as S, O, or N, and amide (CONH) or carbonyl (CO) groups. The acidic substituent may also comprise an α -sulfonamido carboxylic acid group of the formula:











20

















Preferred Spiro Compounds are as follows:


The formula II compounds, a preferred subset of the formula I spirocyclic compounds, which are preferred compounds of the invention include the following compounds, their pharmaceutically-acceptable salts, solvates, and
5 prodrug derivatives, as follows:



































wherein X is F or H, m is zero to four, and n is one to four.


A more preferred subset of the formula I spirocyclic compounds include the following compounds, their pharmaceutically-acceptable salts, solvates, and prodrug derivatives, as follows:















5 wherein X is F or H, m is zero to four, and n is one to four.


A second preferred subset of the formula I spirocyclic compounds include the following compounds, their
 10 pharmaceutically-acceptable salts, solvates, and prodrug derivatives, as follows:















wherein X is F or H.

A second more preferred subset of the formula I
spirocyclic compounds include the following compounds, their
5 pharmaceutically-acceptable salts, solvates, and prodrug
derivatives, as follows:




41



wherein X is F or H.

A most preferred subset of the formula I spirocyclic
 10 compounds include the following compounds, their
 pharmaceutically-acceptable salts, solvates, and prodrug
 derivatives, as follows:














wherein X is F or H , m is zero to four, and n is one to four.

5

A second most preferred subset of the formula I spirocyclic compounds include the following compounds, their pharmaceutically-acceptable salts, solvates, and prodrug derivatives, as follows:

10





5 wherein X is F or H.

The compounds of the invention possess at least one acidic functional substituent (viz., R₃ of Formula I or II) and, as such, are capable of forming salts. Representative
10 pharmaceutically-acceptable salts, include but are not limited to, the alkali and alkaline earth salts such as lithium, sodium, potassium, calcium, magnesium, aluminum and the like. Salts are conveniently prepared from the free acid
15 the acid to an anion exchange resin on the salt cycle.

Included within the definition of pharmaceutically-acceptable salts are the relatively non-toxic, inorganic and organic base addition salts of compounds of the present invention, for example, ammonium, quaternary ammonium, and
20 amine actions, derived from nitrogenous bases of sufficient basicity to form salts with the compounds of this invention (see, for example, S. M. Berge, et. al., "Pharmaceutical Salts," J. Phar. Sci., 66: 1-19 (1977)).

The basic portion of the compounds of the invention
25 (viz., part Q of formula I or II) may be reacted with suitable organic or inorganic acids to form salts of the invention. Representative salts include those selected from the group comprising; acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate,

camsylate, carbonate, chloride, clavulanate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanllate, hexylresorcinolate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, malseate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, palmitate, pantothenate, phosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate, tartrate, tosylate, trifluoroacetate, trifluoromethane sulfonate, and valerate.

The compounds of the formula (I) or (II) can also be in the form of zwitterions, since they contain both acidic and basic functionality and are capable of self-protonation.




Certain compounds of the invention possess one or more chiral centers and may thus exist in optically active forms, or as mixtures of diastereomers. Likewise, when the compounds contain an alkenyl or alkenylene group there exists the possibility of *cis*- and *trans*- isomeric forms of the compounds. The *R*- and *S*- isomers and mixtures thereof, including racemic mixtures as well as mixtures of *cis*- and *trans*- isomers, are contemplated by this invention. Additional asymmetric carbon atoms can be present in a substituent group such as an alkyl group. All such isomers as well as the mixtures thereof are intended to be included in the invention. If a particular stereoisomer is desired, it can be prepared by methods well known in the art by using stereospecific reactions with starting materials which contain the asymmetric centers and are already resolved or, alternatively by methods which lead to mixtures of the stereoisomers and subsequent resolution by known methods.

Prodrug Derivatives of Compounds of the Invention:



Prodrugs are derivatives of the compounds of the invention which have metabolically cleavable groups and become by solvolysis or under physiological conditions the compounds of the invention which are pharmaceutically active

in vivo. For example, ester derivatives of compounds of this invention are often active in vivo, but not in vitro. Other derivatives of the compounds of this invention have activity in both their acid and acid derivative forms, but the acid derivative form often offers advantages of solubility, tissue compatibility, or delayed release in the mammalian organism (see, Bundgard, H., Design of Prodrugs, pp. 7-9, 21-24, Elsevier, Amsterdam 1985). Prodrugs include acid derivatives well known to practitioners of the art, such as, for example, esters prepared by reaction of the parent acid with a suitable alcohol, or amides prepared by reaction of the parent acid compound with an amine. Simple aliphatic or aromatic esters derived from acidic groups pendant on the compounds of this invention are preferred prodrugs. In some cases it is desirable to prepare double ester type prodrugs such as (acyloxy)alkyl esters or ((alkoxycarbonyl)oxy)alkyl esters.


Preferred are the C₁-C₈ alkyl, C₂-C₈ alkenyl, aryl, C₇-C₁₂ substituted aryl, and C₇-C₁₂ arylalkyl esters of the compounds of the invention (per formula I or II) Particularly preferred are the C₁-C₄ alkyl esters, for example, where the R₃ acidic group has been esterified to form a group represented by one of the following formulae:



47



and



5 Acylated basic radicals which are part of basic
group on the compounds of the invention have been found to
significantly enhance bioavailability. Without being bound
by any theory of operation, it is believed that lowering the
basicity of basic group (Q) makes the compounds of this
invention less subject to "food effect", that is, they have
10 good availability in therapeutic administration to an animal
without fasting.


Compounds of this invention may beneficially
be dual prodrug derivatives. For example, the acidic group
(R₃) may be reacted to form an ester and the basic group may
15 additionally be reacted to form an acylated basic derivative.
The prodrug derivatives of the compounds of this invention
may be combined with other features herein taught to enhance
bioavailability, for example, substitution of fluorine atoms
on the basic benzamidine group.

20

Another highly preferred class of prodrugs of the
invention are those formed by acylating the basic radicals
present on the compounds of the invention. The acyl portion
of the acylated basic radical has the general formula:


25

48




where R is C₁-C₈ alkyl, C₂-C₈ alkenyl, aryl, C₇-C₁₂ substituted aryl, and C₇-C₁₂ arylalkyl; and X is a bond, O, S, or N. Preferably R is C₁-C₄ alkyl and X is oxygen. For example, acylated basic radical prodrugs of the invention are prepared and illustrated in A, B, C, and D below:


10 A) acylation of amidine results in a prodrug derivative group:




15 B) acylation of a cyclic amine such as piperidine results in a prodrug derivative group:



20 C) acylation of guanidine results in a prodrug derivative group:



D) acylation of a primary amine results in a prodrug derivative group:



5

where, for A, B, C, and D above, R and X are as defined above for the acylated portion of the basic group.

Preparation of Spiro Compounds:

10 The synthesis of spiro compounds covered by the invention is described in Scheme 1 thru Scheme 11, in which the following terms are used:

P means a general protective group for amines like benzyl, tert.-butoxycarbonyl, benzyloxycarbonyl, or
15 ethoxycarbonyl.

X, when present, is a spacer typically consisting of a chain of up to three carbon atoms, e.g. methylene, dimethylene, or trimethylene.


Scheme Nomenclature:

20 The substituent R is a non-interfering substituent illustrated by an alkyl group selected from ethyl, methyl, or tert.-butyl forming esters containing the group COOR, which are cleaved to the corresponding carboxylic acids (R = H).


25

Scheme 1

50




51




- 5 Scheme 1 describes the synthesis of 1-oxa-3,8-diaza-spiro[4.5]decan-2-ones (see J.M. Caroon, R.D. Clark, A.F. Kluge, J.T. Nelson, A.M. Strosberg, St. H. Unger, A.D. Michel, R.L. Whiting, J. Med. Chem. 1981, 24, 1320). 4-Piperidinone is N-protected, e.g. by reaction with benzyl
- 10 chloroformate, and this compound is converted to the shown epoxide by addition of a methylene group using trimethylsulfoxonium iodide / sodium hydride in DMSO. The ring opening of the epoxide requires heating with an excess of 4-cyanoaniline, and the following formation of the spiro-

oxazolidinone is achieved with N,N'-carbonyl diimidazole, diethyl carbonate, or with phosgene. After removal of the protective group the piperidine is alkylated with an ω -halogenocarboxylate like ethyl bromoacetate or ethyl 4-bromobutanoate. Finally, the nitrile is converted to the amidine by reaction with ethanolic hydrochloric acid followed by treatment with ammonia, and the ethyl ester is cleaved under mild aqueous basic conditions to give the amidino carboxylic acid.








Scheme 2






The synthesis of 3-phenyl-1-oxa-2,8-diaza-spiro[4.5]dec-2-
enes is outlined in Scheme 2. 4-Methylene-piperidines like
5 1-(tert.butoxycarbonyl)-4methylene-piperidine are prepared
from the corresponding N-protected piperidinones by Wittig
reaction. The five-membered ring is formed by addition of 4-
cyanobenzonitrile oxide, which is generated *in situ* from 4-
cyanobenzohydroximinoyl chloride with triethylamine (see K.-
10 C. Liu, B.R. Shelton, R.K. Howe, J. Org. Chem. 1980, 45,
3916; L. Fisera, F. Sauter, J. Fröhlich, Y. Feng, P. Ertl, K.
Mereiter, Monatshefte Chem. 1994, 125, 553). The protective
group is removed with trifluoroacetic acid followed by
alkylation of the spiropiperidine and conversion of the
15 nitrile to the amidine as described in the previous Scheme.


Scheme 3



The synthesis of 2,4-dioxo-1,3,8-triaza-spiro[4.5]decane derivatives is described in Scheme 3. N-protected piperidin-4-ones like 1-benzyloxycarbonyl-piperidin-4-one are converted to the corresponding spirohydantoins by heating with a mixture of potassium cyanide and ammonium carbonate (see G. Winters, V. Aresi, G. Nathansohn, *Farmaco*, Ed. Sci. 1970, 25, 681). The protective group is removed by hydrogenation, and the piperidine is treated with 4-cyanobenzoyl chloride. Alkylation of this intermediate with ω -halogenoalkanoates gives the shown 3-substituted derivatives, and in a second alkylation step the nitrogen at position 1 may be alkylated with alkyl halides R'Hal, e.g. with benzyl bromide leading to 1-benzyl-2,4-dioxo-1,3,8-triaza-spiro[4.5]decanes (see O.O. Orazi, R.A. Corral, H. Schuttenberg, *J. Chem. Soc., Perkin Trans. I*, 1974, 219). The preferred method for conversion of the benzonitrile to an amidine employs the sequence of addition of hydrogen sulfide, alkylation of the intermediate primary thioamide with methyl iodide, heating with ammonium acetate, and purification of the crude amidine after protection with tert.-butoxycarbonyl. In a final step the protective group is removed with trifluoroacetic acid. If the acidic side chain has been masked by an tert.-butyl ester this one is also cleaved under these conditions.


Scheme 4

P = protective group



56

5




- 15 In an alternative sequence 1-substituted 2,4-dioxo-1,3,8-triaza-spiro[4.5]decane derivatives may be prepared as shown in Scheme 4 (see G.M. Carrera, Jr., D.S. Garvey, J. Heterocyclic Chem. 1992, 29, 847). The piperidone is treated with a mixture of potassium cyanide and a primary amine like
- 20 benzyl amine. The intermediate 4-amino-4-cyanopiperidine is hydrolyzed followed by ring closure with potassium cyanate. The following steps including the alkylation of the nitrogen in position 3 with



ω -halogenoalkanoates and formation of the amidine is carried out as described in Scheme 4.

Scheme 5A



5



10




15



Scheme 5A describes the synthesis of 1,3-dioxo-2,8-diaza-spiro[4.5]decane derivatives (see E. Jucker, R. Süss Arch. Pharm. 1961, 294/66, 210; Helv. Chim. Acta 1977, 49, 1135; Y. Ishihara, H. Yukimasa, M. Miyamoto, G. Goto, Chem. Pharm. Bull. 1992, 40, 1177). The shown 2-cyanoacrylate is formed by Knoevenagel condensation between N-protected piperidin-4-ones like N-benzylpiperidinone and ethyl cyanoacetate. It is heated with potassium cyanide in ethanol / water followed by hydrolysis with hydrochloric acid. The diacid may be purified by reesterification followed by another hydrolysis step of the substituted diethyl succinate, and the succinic acid is converted to the spiro succinic anhydride with dehydration reagents like dicyclohexylcarbodiimide (DCC) or acetanhydride. It is treated *in situ* with ω -aminoalkanoates to give the spiroimides. After removal of the protective group the reaction with 4-cyanobenzoyl chloride, formation of the amidine and saponification of the ester are carried out as described before.


20

Scheme 5B



25


59




5

In a similar sequence 2-phenyl-1,3-dioxo-2,8-diaza-spiro[4.5]decanes are prepared. In contrast to Scheme 5A the intermediate succinic anhydride reacts with 4-aminobenzonitrile, and after deprotection of the spiropiperidine the intermediate is alkylated with ω -halogenoalkanoates. The final steps of the synthesis are carried out in the usual manner.

15

Scheme 6



5


Scheme 6 illustrates the synthesis of 2-phenyl-1,3-dioxaspiro[4.5]decanes. N-protected 4-methylenepiperidine epoxides like benzyl 1-oxa-6-aza-spiro[2.5]octane-6-carboxylate are hydrolyzed to 4-hydroxy-4-hydroxymethylpiperidines by heating with diluted aqueous hydrochloric acid (see Eur. Pat. Appl. EP 189 370). The spiro-bicycle is obtained by condensation of the diol with 4-cyanobenzaldehyd, which may be achieved by heating in toluene and catalytic amounts of 4-toluenesulfonic acid or by reaction in the presence of boron trifluoride. The following steps: removal of the protecting group, alkylation with ω -halogenoalkanoates, formation of the amidine, and hydrolysis of the ester; are carried out as described in the previous Schemes.

20


Scheme 7

61

5



10






15

Scheme 7 describes the synthesis of 8-phenyl-1-oxa-3,8-diazaspiro[4.5]decan-2-ones. 1-(4-Cyanophenyl)piperidin-4-ol is prepared by heating a mixture of 4-chlorobenzonitrile and piperidin-4-ol in DMF in the presence of sodium carbonate. The following oxidation to the piperidone is achieved with DMSO / oxalyl chloride (A.J. Mancuso, D. Swern, Synthesis



1981, 165), and the epoxide is formed by reaction with trimethylsulfoxonium iodide / sodium hydride in DMSO. After ring opening by reaction with ω -aminoalkanoates the following steps of formation of the spiro derivative and the amidino acid are carried out according to methods described in Scheme 1.


Scheme 8A

10




15

 $n = 1-3$




- 5 The synthesis of 1-oxa-4,9-diaza-spiro[5.5]undecan-3-ones is described in Scheme 8A (see R.D. Clark, J.M. Caroon, D.B. Repke, A.M. Strosberg, S.M. Bitter, M.D. Okada, A.D. Michel, R.L. Whiting, J. Med. Chem. 1983, 26, 855). N-protected 4-methylenepiperidine epoxides like benzyl 1-oxa-6-aza-
- 10 spiro[2.5]octane-6-carboxylate are opened by heating with a methanolic solution of ammonia to give the corresponding 4-aminomethyl-4-hydroxypiperidine. The spiro-bicyclic nucleus is formed by the following condensation with chloroacetyl chloride. After removal of the benzyloxycarbonyl group with
- 15 HBr in acetic acid the spiropiperidine is acylated with 4-cyanobenzoyl chloride. The subsequent steps of alkylation with ω -halogenoalkanoates, formation of the amidine, and cleavage of the ester are carried out as described in the previous
- 20 Schemes.

Scheme 8B



64



5







10

Scheme 8B illustrates the synthesis of the related 1-oxa-4,9-diaza-spiro[5.5]undecanes. These are prepared by reduction of N(9)-protected 1-oxa-4,9-diaza-spiro[5.5]undecan-3-ones with lithium aluminum hydride. After alkylation with ω -halogenoalkanoates the protective group is removed, and the final steps of the sequence are carried out according to Scheme 8A.

20

Scheme 9

65



5


10


The synthesis of 1,3,8-triaza-spiro[4.5]dec-1-en-4-ones is described in Scheme 9 (see C.A. Bernhart, et al., J. Med. Chem. 1993, 36, 3371; C. del Campo, E.F. Llama, Org. Prep. Proced. Int. 1990, 22, 514). Protected 4-aminopiperidine-4-carboxamides are prepared by addition of potassium cyanide to

15

corresponding piperidin-4-ones like N-benzylpiperidin-4-one followed by hydration of the nitrile intermediate. The spiro-bicyclic nucleus is obtained by heating with triethyl orthoformate or by reaction with gaseous formaldehyde. It is
5 alkylated at the nitrogen in position 3 with ω -halogenoalkanoates and the benzyl group is removed by hydrogenation. After acylation with 4-cyanobenzoyl chloride the amidinocarboxylic acid is prepared according to methods described in the previous Schemes.

Scheme 10






Scheme 10 describes the synthesis of (3-aza-spiro[5.5]undec-9-yl)acetic acid derivatives. After protection of ethyl isonipecotate with benzyl chloroformate the ester is reduced with lithiumaluminum hydride followed by Swern oxidation with oxalyl chloride / DMSO to corresponding 4-formylpiperidine. The spiro derivative is formed by condensation with 1-buten-3-one under basic conditions using potassium hydroxide, and the side chain is introduced by Horner - Emmons reaction with diethyl (ethoxycarbonyl)methylphosphonate / sodium hydride. The bicyclic nucleus and the exocyclic double bond are saturated and the protective group is removed by catalytic hydrogenation with palladium hydroxide on charcoal. The subsequent acylation with 4-cyanobenzoyl chloride, formation of the amidine, and hydrolysis of the ethyl ester are carried out by methods described in the previous Schemes.

Scheme 11a


69



Scheme 11a describes the preparation of 6,5 spiro-fused piperidino-carbamates in which the carbamate nitrogen is substituted with an acetic acid residue and the piperidine nitrogen is acylated with a benzamidine. In the first step, 4-piperidone (1) is allowed to react with TMSCN resulting in the formation of cyanohydrin (3). The nitrile moiety is reduced with LAH providing amino-alcohol (5), which is then allowed to react with diethyl carbonate in the presence of NaH ultimately forming spiro carbamate (7). Alkylation of the carbamate nitrogen is accomplished with NaH and alpha-bromo acetate giving ester (9). Catalytic hydrogenation removes the benzyl group providing free amine (11) which is acylated with 4-cyanobenzoic acid yielding (13). The nitrile moiety in (13) is converted to a protected amidine and is isolated as its Boc derivative. This material is then fully deprotected with TFA providing (15) as a salt.

Scheme 11b


71



Materials containing a 6,6 spiro-fused piperidino-carbamate can be prepared in an analogous fashion (see Scheme 11b).

- 5 Lithio-acetonitrile is allowed to react with 4-piperidone resulting in the formation of alcohol (17). This material can be transformed into final product (23) using the same set of reactions described for the conversion of (1) to (15).

Scheme 11c




Scheme 11c describes the preparation of compounds containing a disubstituted 6,6 and 6,5 spirolactone. In the first step, piperidone 25 is allowed to react with the olefinic grignard reagent giving adduct 27. Oxidation of this material with permanganate affords lactone 29. Alkylation of the lactone enolate with an α-bromo ester provides the functionalized product 31. Removal of the Boc protecting group with TFA liberates amine 33 which can be acylated with 4-cyanobenzoic acid providing adduct 35. The nitrile moiety

in this molecule can be converted to an amidine using the thio-Pinner protocol and then deprotected giving compound 39.

Scheme 12

5



10


Scheme 12 describes the preparation of 3,9-diazaspiro-[5.5]undecane compounds. The diazaspiro skeleton is prepared according to known procedures (see S.M. McElvain and R.E.

Lyle, Jr., *J. Am. Chem. Soc.*, **1967**, 32, 1966). The intermediate diazaspirocyclic compound is alkylated by ω -haloalkanones. After removal of the benzyl group, it is alkylated either by *N*-protected-4-(ω -haloalkyl)piperidines or
5 by corresponding pyridines, which are readily reduced to piperidines by hydrogenation as shown in the experimental section below. In a similar manner, any other basic residue with an appropriate spaced is prepared.

10

Scheme 13

75




$n=1,2$; $m=1-4$; $\text{R}=\text{Me}, \text{Et}, \text{t-Bu}$;

$\text{R}'=(\text{subst.})\text{Ph}, \text{alkyl}$; $\text{Z}=\text{protective group}$

- 5 1-Monoesters of aspartic acid ($n=1$) or glutamic acid ($n=2$), *N*-protected derivatives of these monoesters, or other similarly protected compounds are commercially available or have been described previously in the literature. See

Gregory et al., *J. Chem. Soc. (c)*, **1968**, 715; Olsen et al., *J. Org. Chem.*, **1984**, 49, 3527; Yang and Menifield, *J. Org. Chem.*, **1976**, 41, 1032; Taschner et al., *Liebigs Ann. Chem.*, **1961**, 646, 123, 125, 127, 134. These compounds are connected to sulfonamides by reaction with sulfonyl chlorides. Preferred sulfonyl chlorides are benzenesulfonyl chloride or n-butanesulfonyl chloride. The 3,9-diazaspiro-[5.5]undecane compound from Scheme 12 is acylated by these intermediates, followed by removal of the protective group. It is acylated by *N*-protected ω -aminocarboxylic acids bearing protective groups, such as t-butoxycarbonyl or benzyloxycarbonyl. The protective group is removed and the free amine is converted to a guanidine, which is optionally protected using standard procedures such as by reaction with *N,N'*-bis(t-butoxycarbonyl)thiourea and heavy metal salts (e.g. copper or mercury).

Scheme 14



Scheme 14 outlines the preparation of the 6,5 (n=1) and 6,6 (n=2) spiro-carbamates with substitution of a basic residue on the piperidine nitrogen and an acidic residue on the carbamate nitrogen. The protected compound is

5 deprotonated with sodium hydride in an aprotic solvent, such as tetrahydrofuran, and the resulting sodium salt is reacted with an α -halo ester to provide the mono-substituted products. These compounds are then deprotected to give the secondary amines. These materials are then acylated giving


10 N-alkylated, N-acylated intermediate products. The nitrile group is transformed to an amidino group using a modified thio-Pinner sequence. More specifically, reaction of the nitrile to form the thioamide followed by S-alkylation with methyl iodide, and then displacement with ammonia.

15 Preferably, the intermediate compounds are not isolated but are reacted with di-*t*-butyl dicarbonate to give the protected amidines. These intermediate compounds are fully deprotected, for example with trifluoroacetic acid, to give the desired products.

20

Scheme 15


78




Scheme 15 outlines the preparation of 6,5 spiro-carbamates with substitution of an alkyl guanidine on the piperidine nitrogen, and an acyclic residue on the carbamate nitrogen. The intermediate compound prepared as described in Scheme 14, is acylated with protected amino acids providing the intermediate amide compounds. The protecting groups are then removed using reactions well known in the chemical arts, and materials are guanylated providing the fully-protected intermediate compounds. Complete deprotection, for example with trifluoroacetic acid, provides the desired compounds.

15

Scheme 16



- Scheme 16 describes the synthesis of spiro-carbamates containing an oxygen-linked basic group, where n is 1 or 2.
- 5 The starting compound is alkylated on nitrogen by reacting with a strong base, such as sodium hydride, and an alkylating agent, such as an α -bromo-*t*-butyl acetate. The protecting group for the ketone functional group is then removed, and the ketone reduced with a hydride reducing agent, such as
 - 10 sodium borohydride, to provide a mixture of alcohols. The alcohols are alkylated with 4-cyanobenzyl bromide, and the resulting compound is transformed into the protected amidine.




Scheme 17 describes the synthesis of spiro carbamates containing an amide-linked basic group on the saturated ring.


- 5 The intermediate ketone, prepared as shown in Scheme 16, is reductively aminated with an amine and sodium cyanoborohydride. This intermediate compound is acylated with 4-cyanobenzoic acid providing the amide intermediate. This amide is converted to the protected amidine using
- 10 procedures well known in the chemical arts. The resulting compound is converted into the desired compound using procedures as described previously.

Scheme 18

81



5

Scheme 19

10


Scheme 19 describes the synthesis of 9-benzoyl-2,9-diaza-spiro[5.5]undecanes in which the nitrogen in the 2-position is acylated. The 2,9-diaza-spiro[5.5]undecane template is prepared as described in Example 40 (see also US patent #5,451,578). Treatment of this mono-protected material with 4-cyanobenzoyl chloride (or 2-fluoro-4-cyanobenzoyl chloride) in the presence of a base such as triethylamine gives the benzamide intermediate. The protecting group is removed with trifluoroacetic acid followed by acylation with the appropriate ester-acid chloride such as methyl oxalyl chloride or methyl adipoyl chloride. After mild basic hydrolysis of the ester, the nitrile is converted to the amidine utilizing a three step protocol: 1) treatment with hydrogen sulfide in pyridine in the presence of triethylamine; 2) treatment with methyl iodide in acetone; and 3) treatment with ammonium acetate in ethanol, thus providing the amidino carboxylic acids.

15


20

Scheme 20

5




- 10 Scheme 20 describes the synthesis of 9-benzoyl-2,9-diaza-spiro[5.5]undecanes in which the nitrogen in the 2-position is alkylated. After removal of the protecting group with trifluoroacetic acid in the benzamide intermediate as in Scheme 19, the secondary amine is alkylated with the appropriate halogenoester such as ethyl bromoacetate or ethyl 4-bromobutanoate. Mild basic hydrolysis of the ester followed by nitrile to amidine conversion as described in the previous Scheme
- 15 provides the amidino carboxylic acid.

Scheme 21

5


Scheme 21 describes the synthesis of 2-benzoyl-2,9-diaza-spiro[5.5]undecanes in which the nitrogen in the 9-position is acylated. The mono-protected 2,9-diaza-spiro[5.5]undecane is acylated with the appropriate ester-acid chloride in the presence of triethylamine. Removal of the protecting group with trifluoroacetic acid is followed by acylation with 4-cyanobenzoyl chloride (or 2-fluoro-4-cyanobenzoyl chloride). Mild basic hydrolysis of the ester is followed by conversion of the nitrile to the amidine as previously described for Scheme 19.

10

Scheme 22

5


10 Scheme 22 describes the synthesis of 2-benzoyl-2,9-diaza-spiro[5.5]undecanes in which the nitrogen in the 9-position is alkylated. The mono-protected 2,9-diaza-spiro[5.5]undecane is alkylated with the appropriate halogenoester in the presence of triethylamine. Removal of the protecting group with trifluoroacetic acid is followed by acylation with 4-cyanobenzoyl chloride (or 2-fluoro-4-cyanobenzoyl chloride). Mild basic hydrolysis of the ester is followed by conversion of the nitrile to the amidine as previously described for Scheme 19.

Scheme 23

5

Scheme 23 describes the synthesis of the 8-benzoyl-2,8-diaza-spiro[5.4]decanes in which the nitrogen in the 2-position is acylated. The mono-protected 2,9-diaza-spiro[5.5]undecane nucleus (see: J. Med. Chem. 1995, **38**, 3772-3779) is acylated with 4-cyanobenzoyl chloride (or 2-fluoro-4-cyanobenzoyl chloride). Hydrogenolysis of the benzyl protecting group with palladium on charcoal is followed by acylation with the appropriate ester-acid chloride. Subsequent hydrolysis under mildly basic conditions and then conversion of the nitrile to the amidine as previously described affords the amidino carboxylic acids.

15

Scheme 24

20

Scheme 24 describes the synthesis of the 8-benzoyl-2,8-diaza-spiro[5.4]decanes in which the nitrogen in the 2-position is alkylated. Hydrogenolysis of the benzyl protecting group with palladium on charcoal is followed by alkylation with the


25

appropriate halogenoester. The amidino carboxylic acids are obtained upon hydrolysis of the ester and then conversion of the nitrile, as previously described, to the amidine.

5

Scheme 25

10




Scheme 25 describes the synthesis of the 2-benzoyl-2,8-diaza-spiro[5.4]decanes in which the nitrogen in the 8-position is acylated. The mono-protected 2,8-diaza-spiro[5.4]decane is acylated with the appropriate ester-acid chloride. Hydrogenolysis of the benzyl protecting group with palladium on charcoal is followed by acylation with 4-cyanobenzoyl chloride (or 2-fluoro-4-cyanobenzoyl chloride). Subsequent hydrolysis of the ester under mildly basic conditions and then conversion of the nitrile to the amidine as previously described affords the amidino carboxylic acids.

25

30


Scheme 26

87



- Scheme 26 describes the synthesis of the 2-benzoyl-2,8-diaza-spiro[5.4]decanes in which the nitrogen in the 8-position is alkylated. The mono-protected 2,8-diaza-spiro[5.4]decane is alkylated with the appropriate halogenoester. Hydrogenolysis of the benzyl protecting group with palladium on charcoal is followed by acylation with 4-cyanobenzoyl chloride (or 2-fluoro-4-cyanobenzoyl chloride). Hydrolysis of the ester under mildly basic conditions and then conversion of the nitrile to the amidine as described in Scheme 19 affords the amidino carboxylic acids.

Scheme 27




5

- The Scheme 27 describes the synthesis of (3-aza-spiro[5.5]undec-9-yl)acetic acid derivatives. The ethylisonipecotatate was protected with benzyl chloroformate, then the ester was reduced with lithium aluminum hydride followed by swern oxidation with oxalyl chloride/dimethyl sulfoxide to the corresponding 4-formylpiperidine. The spirocyclic ring was formed by the base catalyzed michael addition of methyl vinyl ketone to the aldehyde followed by acid catalyzed aldol cyclization and dehydration to afford the desired spirocyclic enone. The side chain elongation is carried out by Horner-Emmons condensation with triethylphosphonoacetate/sodium hydride in THF. The bicyclic nucleus and the exocyclic double bond are saturated and the protective group is removed by catalytic hydrogenation. The nitrogen of the aza spirocompound was acylated with p-cyanobenzoyl chloride. The nitrile was converted to N-hydroxyamidino by treating with hydroxylamine hydrochloride in triethylamine and ethanol as solvent. The

hydroxylamidino moiety was hydrogenated with 5% Pd/C (50% wet) at 60 °C using 50 psi H₂ overnight to afford the desired amidino functionality. The catalyst was filtered through celite and solvent evaporated under reduced pressure. The hydrolysis of ester was carried out under basic conditions to give the desired final product.


10

Scheme 28

15

The Scheme 28 describes the synthesis of (2-aza-spiro[5.5]undec-9-yl)acetic acid derivatives. The 3-piperidinemethanol was protected with benzylchloroformate and then oxidized under swern conditions. The subsequent spiro ring formation, Horner-Emmons, acylation, formation of amidine, and hydrolysis of ester were carried out by methods described in previous Scheme 27.

20


Scheme 29

5

The Scheme 29 describes the synthesis of (3-aza-spiro[5.5]undec-9-yl)propionic acid derivatives. The spirocyclic enone was synthesized as shown in Scheme 37, followed by Horner-Emmons reaction with triethylphosphono propionate. The bicyclic nucleus and the exocyclic double bond are saturated and the protective group is removed by catalytic hydrogenation.

The nitrogen of the aza spirocompound was acylated with p-cyanobenzoyl chloride. The nitrile was converted to N-hydroxyamidino by treating with hydroxylamine hydrochloride in triethylamine and ethanol as solvent. The hydroxylamidino moiety was hydrogenated with 5% Pd/C (50% wet) at 60 °C using 50 psi H₂ overnight to afford the desired amidino functionality. The catalyst was filtered through celite and solvent evaporated under reduced pressure. The hydrolysis of ester was carried out under basic conditions to give the desired final product.

20


Scheme 30

5

The Scheme 30 describes the synthesis of (3-aza-spiro[5.5]undec-9-yl)formic acid derivatives (see US Patent No. 5,451,578). The shown diester is formed by Knoevenagel condensation between N-benzylpiperidone and ethyl cyanoacetate. The hydrolysis and esterification is carried out with ethanol and sulfuric acid to give the diester. The diester after purification is reduced to diol with LAH. The debenzylation followed by Boc-protection was carried out in one step by hydrogenation with palladium hydroxide in presence of Boc₂O. The diol was converted to mesylate, followed by condensation with diethylmalonate to afford the spirocyclic diester. The diester was hydrolyzed to diacid followed by decarboxylation to afford the 3-aza-spiro[5.5]undec-9-yl)formic acid. The deprotection with TFA followed by acylation with p-cyanobenzoyl chloride and conversion of nitrile to amidino was carried out utilizing a three step protocol: 1) treatment with hydrogen sulfide in pyridine in the presence of triethylamine; 2)

treatment with methyl iodide in acetone; and 3) treatment with ammonium acetate in ethanol, thus providing the amidino carboxylic acid.


5

Scheme 31

10

The Scheme 35 describes the synthesis 3-{2-[(3-Azaspiro[5.5]undecane-9-carboxylamino) acetic acid. The BOC-acid from Scheme 34 is coupled with glycine ethyl ester or 3-aminoethylpropionate in presence EDC, HOBt, DIEA to afford the amide. The deprotection of Boc followed by acylation with p-cyanobenzoyl chloride, amidino formation, and hydrolysis of ester are carried out as described in the previous schemes.


20

Scheme 32

25 The Scheme 32 describes the synthesis of 8-benzoyl-1,3,8-triaza-spiro[4.5]dec-1-en. The spiro-imidazoline template is synthesized from N-Boc-4-piperidone,

via synthesis of amino nitrile by the strecker reaction. Reduction of amino nitrile with LAH to ethylene diamine. Ethylene diamine is cyclized by mild reaction with formamidine acetate in ethanol at room temperature. The alkylation of spiro-imidazoline with appropriate halogenated alkyl ester gives mixture of N-1 and N-3 alkylated product which can be separated. The protecting group is removed with trifluoroacetic acid and N-8 is acylated with 4-cyanobenzoyl chloride. After basic hydrolysis of ester, the nitrile is converted to amidine utilizing the procedure as described in earlier schemes.


Scheme 33



The Scheme 33 describes the synthesis of 8-aza-spiro[5.4]dec-3-en-2-one in which the nitrogen in the 8-position is alkylated or acylated depending of the derivative being synthesized. The intermediate aza-spiro[4.5]deca-enone template is prepared as described in Scheme 27. The α -bromination of the enone followed by palladium catalyzed coupling with 4-amidinoboronic acid will

give the desired alkylated spiro-alkylated amidine. The reduction of tosylhydrazone of α,β -unsaturated ketones with sodium cyanoborohydride will give the alkene with the double bond migration (see R. O. Hutchins, M. Kaucher, and L. Rua, J. Org. Chem, 1975, 40, 923). The deprotection with TFA followed by alkylation with appropriate halogenated alkylester or acylation with appropriate ester-acid chloride will give the desired N-alkylated or N-acylated intermediates. After mild basic hydrolysis of the ester will give the desired amidino carboxylic acids.


Scheme 34



The Scheme 34 describes the synthesis of 8-benzoyl-2-amino-3-oxa-1,8-diazaspiro[4.5]dec-1-ene in which the nitrogen in the 8-position is acylated. The N-Benzyl-4-piperidone was converted to the corresponding amino nitrile by the strecker reaction (see A. A. Cordi, JM. Lacoste, C. Courchay, PM. Vanhoutte, J. Med. Chem, 1995, 38, 4056). The stepwise hydrolysis of aminonitrile to amino acid followed by reduction of acid to alcohol. The debenzylation is carried out by catalytic hydrogenation and insitu protection with Boc-anhydride. The amino alcohol is cyclized with cyanogen bromide to give spiro-oxazoline ring. The 2-amino is acylated with appropriate ester-acid chloride or alkylated with appropriate halogenated alkylester. The protecting group is removed with trifluoroacetic acid followed by acylation with the 4-cyanobenzoyl chloride (or 2-fluoro-4-cyanobenzoyl chloride) in presence of base such as triethylamine. After


mild basic hydrolysis of ester, the nitrile is converted to the amidine as described in earlier schemes, thus providing the desired amidino carboxylic acids.

Scheme 35




The Scheme 35 describes the synthesis of 2-benzoyl-3-oxa-1,8-diaza-spiro[4.5]dec-1-ene in which the nitrogen in the 2-position is benzoylated. The 2-amino spiro-oxazoline is acylated with 4-cyanobenzoyl chloride. The protecting group is removed with trifluoroacetic acid followed by acylation with appropriate ester-acid chloride. After mild basic hydrolysis of ester, the nitrile is converted to amidino to give the desired product.

Scheme 36



- 5 The Scheme 36 describes the synthesis of 2-benzoyl-3-oxa-1,8-diaza-spiro[4.5]dec-1-ene in which the nitrogen in the 2-position is benzoylated. The 2-amino spiro-oxazoline is acylated with 4-cyanobenzoyl chloride. The protecting group is removed with trifluoroacetic acid followed by alkylation with appropriate halogenated alkylester. After mild basic hydrolysis of ester, the nitrile is converted to amidino to give the desired product.

Scheme 37




5

The Scheme 37 describes the synthesis of (8-benzoyl-aza-spiro[5.4]dec-3-yl)acetic acid derivatives. The reaction of N-benzyl-piperidone with diethyl lithiopyrrolidinomethyl phosphonate will give enamine. The enamine can be directly alkylated with 2-bromo-3-iodopropene, followed by aqueous hydrolysis to give the alkylated aldehyde. The hydrolysis of vinyl bromide can be readily achieved with mercuric acetate and boron trifluoride etherate in glacial acetic acid at room temperature (see S. F. Martin, and T. Chou, J. Org. Chem. 1978, 43, 1027). The γ -keto aldehyde will be treated with aqueous potassium hydroxide in methanol to afford cycloaldolization and dehydration to give the key intermediate spiro[4.5]dienone. The side chain is introduced by Horner-Emmons reaction with triethylphosphonoacetate or triethylphosphono propionate/sodium hydride. The bicyclic nucleus and the exocyclic double bond are saturated and the protective group is removed by catalytic hydrogenation with palladium hydroxide on carbon. The subsequent acylation with 4-cyanobenzoyl chloride or (2-fluoro-4-cyanobenzoyl chloride), formation of amidine, and hydrolysis of the ester are carried out by methods described in the previous Schemes.


25


Scheme 38



- 5 The Scheme 38 describes the synthesis 8-benzoyl-1-(3-acyl-1,3-dihydroimidazo[4,5-b]pyridin-2-yl)-8-azaspiro[5.5]undec-1-en. The mono protected spiro-imidazoline from Scheme 33 is acylated with appropriate ester-acid chloride. The protecting group is removed followed with acylation with 4-cyanobenzoyl chloride (or 2-fluoro-4-cyanobenzoyl chloride) in presence of base such as triethylamine. After ester hydrolysis, the nitrile is converted to amidine functionality as described in earlier schemes.
- 10

Scheme 39



Scheme 40

5


Scheme 40 describes the synthesis of a lactam. The imide was reduced with LiAlH₄ in THF to afford the amine. It was then N-debenzylated under hydrogenolysis conditions. The free piperidino compound was reacted with carboxy group bearing compounds as described before. De-protection of the

10

carboxy groups followed by conversion of the cyano to amidino yielded the desired compounds.

Scheme 41

5




Scheme 41 1-Benzylpiperidone was condensed with 4-methoxybenzylamine followed by reaction with potassium cyanide. The cyano group was hydrolysed by reaction with hot conc. HCl. Then it was coupled with 4-carboxyamido aniline to afford the amide. The 4-methoxy benzyl protective group was removed by reaction with DDQ, followed by reaction of the free amine with carbonyl diimidazole to give rise to urea derivative. N-De-benzylation was achieved under

10

hydrogenolysis conditions, followed by coupling with carboxy group bearing synthons.

Scheme 42


5




10

Scheme 42 1-Benzylpiperidone was condensed with ethyl cyanoacetate and ammonia in ethanol as described in the literature (S.M. McElvain, R.E. Lyle, Jr.; J. Amer. Chem. Soc. 72, 384 (1950)). This was then treated with conc. HCl at reflux for 3 days to afford the diacid, which was purified by its conversion to

diethylester followed by hydrolysis back to diacid. This was then converted to the anhydride, and treated with 4-carboxyamido aniline as described in scheme 1 to afford the imide. This imide was converted to lactam by reaction with NaBH₄ as described in Scheme 39. The rest of the sequence was carried out as described elsewhere in this application.

Scheme 43

Scheme 43 1-Benzylpiperidone was coupled with 4-carboxyamido aniline, and the imide was reacted with potassium cyanide. This amine nitrile was reacted with potassium cyanate under acidic conditions to yield the hydantoin. The hydantoin functionality was reduced to urea by reaction with NaBH₄, as described before.

Scheme 44

5

Scheme 44 1-Benzylpiperidone was coupled with 4-methoxy benzylamine, and the imine was then reacted with 4-carboxamide aniline to yield the amine nitrile. The 4-methoxy benzyl group was deprotected by reaction with DDQ. The free amine thus obtained was treated with potassium cyanate under acidic conditions to afford the hydantoin. The rest of the sequence is described elsewhere in this patent.

15

5

10

15

20


25

30


35

Scheme 45

106



Scheme 45 1-Benzylpiperidinewas coupled with ethyl cyanoacetate to afford the
 addition product, which was then reacted with potassium cyanide in
 ethanol/water at reflux to yield the dinitrile. It was reduced with LiAlH_4 to afford
 the diamine. It was then reacted with carbonyl diimidazole to yield the 7-
 membered urea. This was subjected to N-debenzylation followed by coupling of
 the free piperidino compound with 4-cyano phenyl triflate under palladium
 catalysis. The rest of the sequence is described elsewhere.


Scheme 46

Scheme 46 4-carboxamide aniline was reacted with the epoxide (synthesis of it is described elsewhere in this application) to afford the aminol. The hydroxy group was protected as tert-butyl dimethylsilyl ether, and the amine was then reacted with chloroacetyl chloride. Then the TBS protective group was removed and the free hydroxy compound was cyclized to yield the spiro compound. the rest of the steps are identical to procedures described in other schemes


The following Examples illustrate the practice of the
5 invention.

Example 1

Preparation of
Ethyl (3-(4-(Aminoiminomethyl)benzoyl)-3-aza-spiro[5.5]undec-
10 9-yl)acetate Hydrochloride:



Step A: Preparation of benzyl 9-oxo-3-aza-spiro[5.5]undec-
15 7-ene-3-carboxylate




20 A solution of 0.98 g (3.96 mmol) benzyl 4-formylpiperidine-1-carboxylate (prepared by the method from Eur. J. Med. Chem. 1991, 26, 625) and 0.28 g (4.0 mmol) 3-buten-2-one in a mixture of 1 ml methanol and 1 ml water was added dropwise to a boiling solution of 0.015 g (0.27 mmol) potassium hydroxide

in 1 ml methanol. After 1 hour heating with reflux the cooled mixture was poured into 50 ml water, and it was extracted with tert.-butylmethylether. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The
5 title compound was obtained from the remaining oil by HPLC on silica gel with hexane / acetone 4:1.

yield: 0.23 g (19 %) oil


Step B: Preparation of benzyl 9-
10 ((ethoxycarbonylmethylene)-3-aza-spiro[5.5]undec-7-ene-3-carboxylate



15 23.63 g (105.4 mmol) diethyl ethoxycarbonylmethylphosphonate were dissolved in 500 ml dry THF, and the solution was kept under an atmosphere of nitrogen. After addition of 3.07 g (102.3 mmol) 80 % sodium hydride in mineral oil the mixture was stirred for 30 min at 0 °C. A solution of 30.0 g (100.2
20 mmol) of the spiro compound from the previous step in 33 ml dry THF was added dropwise, and it was stirred for 4 hours with warming to room temperature. The mixture was poured into water, and it was extracted with tert.-butylmethylether. The organic layer was washed two times with water and dried over
25 sodium sulfate, and the solvent was removed in vacuo. The title compound was purified by chromatography on silica gel with hexane / acetone 4:1 and obtained in five oily fractions each of them containing some impurities. They were combined and used for the next step.
30 Total yield: 10.58 g (29 %)

Step C: Preparation of ethyl (3-aza-spiro[5.5]undec-9-yl)acetate

110




9.6 g (26.0 mmol) of the protected spiro compound from Step B
5 were dissolved in 400 ml ethanol, and the solution was filled
into a hydrogenation vessel followed by 2 g Pd(II) hydroxide
on charcoal. The reaction was carried out at 40 °C and 1 atm
hydrogen, and it was complete after about 40 hours. The
catalyst was removed by filtration through silica gel, and
10 the filtrate was concentrated under reduced pressure. The
remaining oil was treated with dry ether, filtered, and the
filtrate was acidified with ethereal hydrochloric acid. The
hydrochloride of the title compound was collected by
filtration, washed two times with ether, dissolved in water,
15 and the solution was made alkaline with 2 N aqueous sodium
hydroxide solution. After extraction with dichloromethane the
organic layer was dried over sodium sulfate and concentrated
in vacuo.

yield: 3.43 g (55 %) oil

20

Step D: Preparation of ethyl (3-(4-cyanobenzoyl)-3-aza-
spiro[5.5]undec-9-yl)acetate



25

0.24 g (1.0 mmol) of the compound from the previous step and
0.6 ml dry pyridine were dissolved in 7 ml dry THF. The

solution was kept below 5 °C, while 0.165 g (1.0 mmol) 4-cyanobenzoyl chloride in 6 ml dry THF were added dropwise within 15 min. After 2 hours stirring at room temperature it was concentrated under reduced pressure. The residue was
5 treated with water and extracted with ethyl acetate. The organic layer was washed with diluted aqueous Cu(II) sulfate solution, dried over sodium sulfate, and the solvent was removed in vacuo. The title compound was obtained by HPLC on silica gel with hexane / acetone 4:1 followed by 3:1.
10 yield: 0.19 g (51 %) yellow oil

Step E: Preparation of ethyl (3-(4-(aminoiminomethyl)benzoyl)-3-aza-spiro[5.5]undec-9-yl)acetate hydrochloride


15 A solution of 1.65 g (4.48 mmol) of the nitrile from the previous step in 75 ml ethanol was kept below 5 °C and saturated with gaseous hydrogen chloride. It was stirred over night at room temperature until the reaction was complete,
20 and the solvent was removed under reduced pressure to give the crude intermediate imidoester. It was treated with 50 ml 12 % ethanolic ammonia solution and stirred for two days at room temperature. The mixture was concentrated in vacuo, and the residue was stirred with 10 ml dichloromethane. Remaining
25 solids were removed by filtration, and the solvent was evaporated from the filtrate under reduced pressure. The crude title amidine was obtained by chromatography on silica gel with dichloromethane containing between 5 % and 10 % ethanol. It solidified by stirring several times with ether,
30 and it was further purified by HPLC using the same eluent.
yield: 0.18 g (9.5 %) colorless crystals, m.p. > 300 °C
ELISA: IC₅₀ > 10 µM PRP (ADP): IC₅₀ = 100 µM

Example 2

35

Preparation of

(3-(4-(Aminoiminomethyl)benzoyl)-3-aza-spiro[5.5]undec-9-yl)acetic Acid Hydrochloride



. HCl

5

70 mg (0.166 mmol) of the ester from Example 1 were treated with 2 ml 2 N aqueous hydrogen chloride and 5 ml water. After heating for 4 hours at 60 °C the solvent was removed under reduced pressure, and the remaining title acid was stirred with tert.-butylmethylether, collected by filtration, and dried in vacuo.

yield: 64 mg (98 %) beige hygroscopic solid

ELISA: IC₅₀ = 0.0082 μM PRP (ADP): IC₅₀ = 0.41 μM


15

Example 3

Preparation of

Ethyl 4-(3-(4-(Aminoiminomethyl)phenyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-8-yl)butanoate Hydrochloride


20



Step A: Preparation of benzyl 4-((N-(4-

cyanophenyl)amino)methyl)-4-hydroxypiperidine-1-carboxylate

5



A mixture of 20.0 g (80.9 mmol) benzyl 1-oxa-6-aza-

spiro[2.5]octane-6-carboxylate (prepared from the protected

10 piperidone and dimethylsulfoxonium methylide according to J.

Med. Chem. 1983, 26, 855; US Patent 4,353,901) and 47.0 g

(397.8 mmol) 4-aminobenzonitrile were heated at 160 °C for 30

hours until no starting epoxide could be detected by TLC. It

was cooled to room temperature, and the excess of the aniline

15 was removed by chromatography on silica gel with

dichloromethane. The title compound was obtained after

enhancing the polarity of the eluent by addition of 5 %


ethanol.

20

yield: 24.5 g (83 %) beige crystalline solid, m.p.107-108 °C


Step B: Preparation of benzyl (3-(4-cyanophenyl)-2-oxo-1-

oxa-3,8-diaza-spiro[4.5]dec-8-yl)carboxylate



A solution of 18.5 g (50.6 mmol) of the piperidine from Step A and 11.45 g (70.6 mmol) N,N'-carbonyldiimidazole in 210 ml
5 dry THF were heated with reflux for 8 hours under an atmosphere of argon. After addition of another 5.0 g (30.8 mmol) carbonyldiimidazole heating was continued overnight. The solvent was removed under reduced pressure, and the title compound was obtained by chromatography on silica gel with
10 dichloromethane. It solidified from the combined pure fractions by stirring with hexane, was filtered, and dried in vacuo.
yield: 5.3 g (27 %) pale yellow powder, m.p. 138-140 °C

15 Step C: Preparation of 4-(2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-3-yl)benzonitrile trifluoroacetate




20 4.26 g (10.88 mmol) of the protected spiro compound from the previous step were added in small portions to 26 ml trifluoroacetic acid, while the temperature was kept below 10 °C. After two days stirring at room temperature the mixture was poured into ice water and neutralized with sodium

bicarbonate. It was treated with dichloromethane, and a precipitate of the title compound was formed between the two layers, which was collected by filtration and dried in vacuo. yield: 4.0 g (99 %) colorless crystals, m.p. 217-220 °C

5

Step D: Preparation of ethyl 4-(3-(4-cyanophenyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-8-yl)butanoate



10


3.0 g (8.08 mmol) of the piperidine from the previous step were dissolved in 50 ml dry acetone followed by addition of 1.68 g (15.85 mmol) sodium carbonate and 1.56 g (8.00 mmol) ethyl 4-bromobutanoate. The mixture was heated with reflux overnight, cooled to room temperature, and the inorganic solids were removed by filtration. The filtrate was concentrated under reduced pressure, and the title compound was obtained from the residue by chromatography on silica gel with dichloromethane / ethanol 40:1 and 20:1. The combined pure fractions solidified, and the crystalline ester was dried in vacuo at 50 °C. yield: 2.4 g (81 %) colorless crystals, m.p. 78-80 °C

15

20

Step E: Preparation of ethyl 4-(3-(4-(ethoxycarbonimidoyl)phenyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-8-yl)butanoate hydrochloride

25



A suspension of 2.4 g (6.46 mmol) of the nitrile from Step D in 140 ml dry ethanol was saturated with gaseous hydrogen chloride, while the temperature was kept below 10 °C. It was stirred overnight at room temperature, and the solvent was removed under reduced pressure. The title intermediate crystallized by stirring with hexane. It was filtered with suction and dried in vacuo.

10 yield: 2.2 g (75 %) pale yellow powder, m.p. 195-199 °C

Step F: Preparation of ethyl 4-(3-(4-(aminoiminomethyl)phenyl)-2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-8-yl)butanoate hydrochloride

15 2.2 g (4.85 mmol) of the intermediate from the previous step were suspended in 130 ml saturated ethanolic ammonia solution. It was stirred overnight at room temperature, and after addition of another 30 ml ammonia solution stirring was continued for another day. The solvent was removed under reduced pressure., and the title amidine was obtained by chromatography on silica gel with dichloromethane / ethanol 2:1. It crystallized by stirring with tert.-butylmethylether, was filtered with suction, and dried in vacuo at 50 °C.


20 25 yield = 0.55 g (27 %), white powder, m.p. 127-129 °C

ELISA: not tested PRP (ADP): not tested


Example 4

Preparation of

4-(3-(4-(Aminoiminomethyl)phenyl)-2-oxo-1-oxa-3,8-diaza-
5 spiro[4.5]dec-8-yl)butanoic Acid Bistrifluoroacetate



Step A: Preparation of tert.-butyl 4-(3-(4-cyanophenyl)-2-
10 oxo-1-oxa-3,8-diaza-spiro[4.5]dec-8-yl)butanoate




15

10.0 g (26.9 mmol) of the intermediate from Example 3, Step C
were dissolved in 250 ml dry acetone followed by addition of
5.7 g (53.8 mmol) sodium carbonate and 4.81 g (26.9 mmol)
tert.-butyl 4-chlorobutanoate (prepared according to Chem.
Ber. 1965, 98, 2312). It was heated with reflux overnight.
20 After addition of another 2.85 g (26.9 mmol) sodium carbonate
and 2.4 g (13.4 mmol) of the tert.-butyl ester heating was
continued for another day. The inorganic solids were removed

by filtration, and the filtrate was concentrated under reduced pressure. The title nitrile was obtained as an oil, which solidified upon standing after chromatographic purification on silica gel with dichloromethane / ethanol 40:1 and 20:1.
yield: 1.87 g (17 %) beige amorphous solid, m.p. 92-94 °C

Step B: Preparation of tert.-butyl 4-(3-(4-((tert.-butoxycarbonylamino)iminomethyl)phenyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-8-yl)butanoate



A steady stream of gaseous hydrogen sulfide was passed through a solution of 1.8 g (4.5 mmol) of the nitrile from the previous step in 67.5 ml dry pyridine and 7.2 ml triethylamine for about 1 hour. After stirring over night the conversion to the thioamide was complete. The mixture was poured into water and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate, and concentrated in vacuo. It was dissolved in 100 ml toluene, evaporated again under reduced pressure, and this procedure was repeated for two times to remove remaining pyridine.

The crude thioamide was suspended in 22.5 ml acetone followed by dropwise addition of 2.25 ml methyl iodide. It was stirred for 1 hour at room temperature, while the mixture became a

clear solution, and evaporated to dryness in vacuo. The residue was treated with 18 ml methanol followed by 1.35 g (17.5 mmol) ammonium acetate, and the mixture was heated for 3 h at 60 °C. After evaporation under reduced pressure the remaining oil was stirred two times with tert.-butylmethylether to leave the crude crystalline amidine.

It was added to the amidine a mixture of 45 ml THF / water 1:1 followed by 4.05 g (29.3 mmol) potassium carbonate and 4.5 g (20.6 mmol) Boc₂O. After 45 min. stirring at room temperature it was diluted with 50 ml water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure. The title compound was obtained by chromatography on silica gel with dichloromethane / ethanol 20:1 followed by another chromatographic purification with dichloromethane / ethanol 40:1.

yield: 0.2 g (8.6 %) yellow oil

Step C: Preparation of 4-(3-(4-(aminoiminomethyl)phenyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-8-yl)butanoic acid bistrifluoroacetate


0.2 g (0.39 mmol) of the protected amidine from Step B were treated with 2 ml trifluoroacetic acid, and the mixture was stirred at room temperature for 2 hours. It was evaporated to dryness in vacuo, and the solid residue was stirred several times with ether and with hexane. The title acid was collected by filtration and dried at 50 °C in vacuo.

yield: 0.12 g (53 %), beige crystalline solid, m.p.122-125 °C


ELISA: not tested PRP (ADP): IC₅₀ = 3 µM

Example 5

Preparation of Ethyl (3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)acetate Hydrochloride



Step A: Preparation of tert.-butyl (3-(4-cyanophenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)carboxylate



4-Cyanobenzohydroximinoyl chloride was prepared by chlorination of 4-cyanobenzaldehyde oxime with N-chlorosuccinimide according to the procedure from J. Org. Chem. 1980, 45, 3916 and tert.-butyl 4-methylenepiperidine-1-carboxylate according to the procedure from Int. Pat. Appl. WO 94 / 13696.


To a solution of 15.82 g (80.2 mmol) of the piperidine and 14.48 g (80.2 mmol) of the hydroximinoyl chloride in 150 ml dry methanol was added dropwise the same volume of a methanolic solution of 17.8 ml triethylamine, while the temperature was kept below 28 °C. After stirring at room temperature for two days another 8.7 g (48.2 mmol) of the hydroximinoyl chloride and 10.7 ml triethylamine were added

in three equal portions, each after a period of 2 hours. It was stirred over night, and the precipitate of the title compound was collected by filtration and washed with methanol. The crystals were stirred with tert.-

5 butylmethylether, filtered with suction, and dried in vacuo. The combined filtrates were poured into water and extracted three times with tert.-butylmethylether. The combined extracts were dried over sodium sulfate, concentrated under reduced pressure to leave another crop of the title compound,
10 which was washed with a small amount of methanol and dried in vacuo.

total yield: 26.0 g (95 %) white powder, m.p. 169-171 °C

Step B: Preparation of 4-(1-oxa-2,8-diaza-spiro[4.5]dec-2-en-3-yl)benzonitrile
15




10.0 g (29.3 mmol) of the protected piperidine from the
20 previous Step were added in small portions to 25 ml trifluoroacetic acid, while the temperature was maintained below 30 °C. After 3 hours stirring at room temperature the mixture was carefully poured into saturated aqueous sodium bicarbonate solution and stirred for 20 min. A first crop of
25 the title piperidine precipitated from the mixture and was collected by filtration, dried in vacuo at 40 °C, stirred with ethyl acetate, and filtered again. The aqueous filtrate was adjusted to pH 11 with 2 N sodium hydroxide solution and extracted four times with ethyl acetate. The combined organic
30 layers were dried over sodium sulfate, and two other crops were formed by gradual concentration under reduced pressure,

which were washed with a small amount of ethyl acetate and filtered with suction.

total yield: 6.94 g (98 %) colorless crystals, m.p. > 199 °C (dec.)

5

Step C: Preparation of ethyl (3-(4-cyanophenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)acetate



10

0.6 g (2.5 mmol) of the piperidine from Step B were dissolved in a mixture of 10 ml dry DMF and 10 ml dry ethanol followed by addition of 0.69 g (5.0 mmol) potassium carbonate. After 15 30 min stirring 0.42 g (2.5 mmol) ethyl bromoacetate were added dropwise, and the mixture was stirred overnight at room temperature. It was poured into water and extracted two times with ethyl acetate. The combined organic layers were washed two times with water, dried over sodium sulfate, and 20 concentrated under reduced pressure. The title compound was obtained from the residue by chromatography on silica gel with hexane / acetone 3:2 as an oil, which solidified upon standing.

yield: 0.52 g (64 %) pale yellow crystals, m.p. 116-118 °C

25

Step D: Preparation of ethyl (3-(4-(aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)acetate hydrochloride

30

A solution of 0.5 g (1.53 mmol) of the nitrile from the previous Step in 35 ml dry ethanol was saturated with gaseous

hydrogen chloride at 0 °C. The mixture was stirred overnight at room temperature, concentrated under reduced pressure, and treated with 40 ml of a saturated ethanolic solution of ammonia. After stirring over night another 10 ml of the ammonia solution were added, and the reaction was brought to completion by standing at room temperature for another two days. The solvent was removed in vacuo, and the remaining solid title compound was purified by stirring with ethyl acetate, filtration, and chromatography on silica gel with dichloromethane / methanol 4:1.

yield: 0.23 g (40 %), white powder, m.p. > 254 °C (dec.)


ELISA: not tested PRP (ADP): not tested

15

Example 6

Preparation of

(3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl)acetic Acid



20


0.12 g (0.315 mmol) of the ester from Example 5 were dissolved in 2 ml ethanol, and after addition of 0.4 ml 2 N aqueous sodium hydroxide solution the mixture was stirred overnight at room temperature. It was adjusted to pH 4 with diluted acetic acid. The solvent was removed from the clear solution under reduced pressure to leave a brown oil, which solidified by stirring with a mixture of ethanol and water. It was filtered, stirred in a small amount of hot ethanol, filtered again, and dried in vacuo.

yield: 88 mg (88 %) colorless amorphous solid, m.p. > 265 °C
ELISA: not tested PRP (ADP): IC₅₀ = 4 µM

Example 7


5 Preparation of

Ethyl 4-(3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)butanoate Hydrochloride



10

Step A: Preparation of ethyl 4-(3-(4-cyanophenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)butanoate



15

1.2 g (5.0 mmol) of the piperidine from Example 5, Step B, 1.37 g (9.9 mmol) potassium carbonate, and a catalytic amount of potassium iodide were suspended in 30 ml dry acetone followed by addition of 0.99 g (5.1 mmol) ethyl 4-bromobutanoate. The mixture was heated with reflux overnight, cooled to room temperature, diluted with water, and extracted three times with ethyl acetate. The combined organic layers were washed with water, dried over sodium sulfate, and

20

concentrated under reduced pressure. The title compound was purified by chromatography on silica gel with dichloromethane containing 5 % ethanol and recrystallized from ether.
yield: 0.59 g (33 %) white powder, m.p. 85-88 °C

5

Step B: Preparation of ethyl 4-(3-(4-(aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)butanoate hydrochloride


10 0.58 g (1.63 mmol) of the nitrile from Step A were dissolved in 35 ml dry ethanol and converted to the title amidine as described for Example 5, Step D. It was purified by chromatography on silica gel with dichloromethane / methanol 7:3.

15 yield: 0.4 g (60 %) colorless foam
ELISA: not tested PRP (ADP): IC₅₀ = 2.8 µM

Example 8

Preparation of

20 4-(3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)butanoic Acid



0.28 g (0.685 mmol) of the ethyl ester from Example 7 were
25 hydrolyzed in a mixture of 4 ml ethanol and 0.9 ml 2 N aqueous sodium hydroxide solution according to the procedure from Example 6. The title acid crystallized from water / ethanol 1:2, and it was filtered and dried in vacuo.


yield: 0.09 g (38 %), colorless crystals, m.p. > 185 °C
(dec.)

ELISA: not tested PRP (ADP): IC₅₀ = 0.32 μM

5


Example 9

Ethyl 4-(3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)-4-oxobutanoate Hydrochloride



10

Step A: Preparation of 4-(3-(4-cyanophenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)-4-oxobutanoic acid



15

To a suspension of 1.2 g (5.0 mmol) of the intermediate from Example 5, Step B in 30 ml dry THF were added 0.5 g (5.0 mmol) succinic anhydride and 60 mg 4-N,N-dimethylaminopyridine (DMAP). After 30 min. heating with reflux another 0.15 g (1.5 mmol) succinic anhydride were added and refluxing was continued from 1.5 hours. The solvent was removed under reduced pressure, and the title compound

20

was obtained by chromatography on silica gel with dichloromethane / ethanol 9:1. It was recrystallized from ether, filtered, and dried in vacuo.

yield: 0.98 g (58 %) white powder, m.p. 167-170 °C

5

Step B: Preparation of ethyl 4-(3-(4-(aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)-4-oxobutanoate hydrochloride

- 10 A solution of 0.98 g (2.87 mmol) of the nitrile from Step A in 65 ml dry ethanol was converted to the amidine with by saturation with hydrogen chloride followed by addition of 65 ml saturated ethanolic ammonia solution as described for Example 5, Step D. It was purified by chromatography on
15 silica gel with dichloromethane / ethanol 4:1.
yield: 0.48 g (40 %), oil which solidified upon standing


ELISA: not tested PRP (ADP): not tested

20

Example 10

Preparation of
4-(3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)-4-oxobutanoic Acid

25



0.34 g (0.8 mmol) of the ethyl ester from Example 9 were hydrolyzed in a mixture of 5 ml ethanol and 1 ml 2 N aqueous sodium hydroxide solution according to the procedure from


Example 6. A first crop (200 mg) of the title acid crystallized from water / ethanol 1:2. The mother liquid was concentrated, and a second crop (60 mg) was obtained by stirring with a mixture of ethyl acetate and ether. The crystals were filtered and dried in vacuo.
total yield: 0.26 g (90 %) white powder, m.p. > 255 °C (dec.)

ELISA: not tested PRP (ADP): IC₅₀ = 1 µM


Example 11

Preparation of

Ethyl 4-(9-(4-(Aminoiminomethyl)benzoyl)-3-oxo-1-oxa-4,9-diaza-spiro[5.5]undec-4-yl)butanoate Hydrochloride




Step A: Preparation of 9-(4-cyanobenzoyl)-3-oxo-1-oxa-4,9-diaza-spiro[5.5]undecane



18.0 g (71.7 mmol) 3-oxo-1-oxa-4,9-diaza-spiro[5.5]undecane hydrobromide (prepared according to J. Med. Chem. **1983**, 26, 855) were dissolved in 300 ml dry pyridine, and 11.9 g (71.9 mmol) 4-cyanobenzoyl chloride were added in small portions. The mixture was stirred over night at room temperature and evaporated under reduced pressure. The residue was dissolved in toluene, which was removed in vacuo. This process was repeated two times to remove remaining pyridine. It was treated with water and neutralized by addition of saturated aqueous sodium bicarbonate solution. The precipitate of the title compound was filtered with suction, washed with water, and dried in vacuo.

yield: 13.6 g (63 %) white powder, m.p. 250 - 251 °C

Step B: Preparation of ethyl 4-(9-(4-cyanobenzoyl)-3-oxo-1-oxa-4,9-diaza-spiro[5.5]undec-4-yl)butanoate



A mixture of 2.99 g (10.0 mmol) of the compound from the previous step and 100 ml dry DMF was warmed to 60 °C followed
5 by addition of 0.44 g (11.0 mmol) sodium hydride (60 % in mineral oil). It was kept with stirring for 30 min at this temperature until a clear solution was obtained. 2.14 g (10.97 mmol) ethyl 4-bromobutanoate were added dropwise after cooling to room temperature. The mixture was stirred over
10 night, concentrated to dryness under reduced pressure, and treated with water and ethyl acetate. 1.7 g of remaining insoluble starting material was recovered by filtration. The organic layer was washed two times with brine, dried over sodium sulfate, and concentrated in vacuo. The title ester
15 was obtained by chromatography on silica gel with ethyl acetate / ethanol 9:1.
yield: 0.8 g (19 %) oil

20 Step C: Preparation of ethyl 4-(9-(4-(4-(aminoiminomethyl)benzoyl)-3-oxo-1-oxa-4,9-diazaspiro[5.5]undec-4-yl)butanoate hydrochloride

A solution of 0.8 g (1.93 mmol) of the nitrile from the
25 previous step in 50 ml dry ethanol was kept at 10 °C and saturated with gaseous hydrogen chloride. It was stirred over night at room temperature and concentrated to dryness under reduced pressure to leave the crude intermediate iminoester,

which was treated with 50 ml 15 % ethanolic ammonia and stirred again over night. The solvent was removed *in vacuo*, and the title amidine was obtained by chromatography on silica gel with ethanol / ethyl acetate 7:3.

5 yield: 0.11 g (12 %) colorless foam

ELISA: not tested


PRP (ADP): not tested

10

Example 12

Preparation of

4-(9-(4-(Aminoiminomethyl)benzoyl)-3-oxo-1-oxa-4,9-diaza-spiro[5.5]undec-4-yl)butanoic Acid Hydrochloride



To a solution of 75 mg (0.16 mmol) of the ester from Example 11 in 10 ml ethanol was added 1 ml 2 N aqueous sodium hydroxide solution, and the mixture was stirred over night at room temperature. It was concentrated to dryness *in vacuo*, and the residue was dissolved in a small amount of water. It was acidified with 1 ml aqueous 2 N hydrochloric acid and the solvent was removed under reduced pressure. The residue was stirred several times with ethanol. The combined extracts

20

25

were filtered through a plug of cotton wool and concentrated to dryness *in vacuo* to leave the pure title acid.


yield: 58 mg (82 %) colorless foam

5 ELISA: not tested PRP (ADP): $IC_{50} > 10 \mu M$


Example 13

Preparation of

- 10 (8-(4-(Aminoiminomethyl)benzoyl)-1-phenylmethyl-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl)acetic Acid Trifluoroacetate



- 15 Step A: Preparation of benzyl 4-benzylamino-4-cyanopiperidine-1-carboxylate hydrochloride



- 20 11.65 g (50 mmol) N-(benzyloxycarbonyl)piperidone (prepared from 4-piperidone and benzyl chloroformate according to Chem. Pharm. Bull. 1982, 30, 1084) and 7.2 g (50 mmol) benzylamine


hydrochloride were dissolved in a mixture of 20 ml methanol and 10 ml water. The solution was kept at 0 °C, while 15 ml of an aqueous solution of 3.26 g (50 mmol) potassium cyanide were added dropwise. After stirring overnight at room

5 temperature a crystalline solid had been formed, which was collected by filtration. The filtrate was treated with a mixture of water and ether. The organic layer was separated and the aqueous layer extracted with ether. The combined organic layers were dried over sodium sulfate and added to
10 the solid material. The title hydrochloride precipitated after treating with a saturated ethereal solution of hydrogen chloride, and it was isolated by filtration and dried in vacuo.

yield: 18.25 g (95 %) white powder, m.p. 143-145 °C (dec.)

15

Step B: Preparation of benzyl 1-benzyl-2,4-dioxo-1,3,8-triaza-spiro[4.5]decane-8-carboxylate




20 To a solution of 17.3 g (44.8 mmol) of the piperidine from the previous Step in 30 ml acetic acid were added 15 ml of an aqueous solution of 7.3 g (90.0 mmol) potassium cyanate. The mixture became a clear solution with slight warming. It was stirred for 30 min at room temperature followed by 45 min at
25 55 °C and poured into ice water. The aqueous solution was extracted two times with ethyl acetate, and the organic layer was concentrated in vacuo. The residue was treated with 45 ml 10 % aqueous hydrochloric acid. It was kept at 55 °C for 15 min and diluted with water. After two extractions with ethyl
30 acetate the combined extracts were washed with aqueous sodium

bicarbonate solution, dried over sodium sulfate, and concentrated in vacuo. The remaining oil of the pure title hydantion slowly solidified upon standing.

yield: 13.25 g (75 %) colorless amorphous solid,

5 m.p. 123-125 °C

Step C: Preparation of 1-phenylmethyl-2,4-dioxo-1,3,8-triaza-spiro[4.5]decane




10

8.0 g (20.3 mmol) of the protected piperidine from Step C were dissolved in 100 ml ethanol. After addition of 500 mg 10 % Pd/C the mixture was filled into an autoclave and hydrogenated for 32 hours at 50 atm hydrogen and 50 °C. The catalyst was removed by filtration, and the solution was concentrated under reduced pressure. The title compound was obtained from the residue by chromatography on silica gel with dichloromethane containing from 5 % to 20 % ethanol. yield: 1.8 g (34 %) pale yellow amorphous solid,

15 m.p. 195-196 °C

Step D: Preparation of 8-(4-cyanobenzoyl)-1-phenylmethyl-2,4-dioxo-1,3,8-triaza-spiro[4.5]decane

135




1.7 g (6.56 mmol) of the piperidine from the previous Step were dissolved in a mixture of 50 ml dry THF and 8 ml dry
5 pyridine. After cooling with ice 1.1 g (6.64 mmol) 4-cyanobenzoyl chloride were added. It was stirred overnight at room temperature and poured into ice water. After two extractions with ethyl acetate the combined organic layers were successively washed two times with saturated aqueous
10 Cu(II) sulfate solution and with brine. It was dried over sodium sulfate and concentrated under reduced pressure. The title compound was isolated from the residue by chromatography on silica gel with dichloromethane containing 4 % ethanol.
15 yield: 0.92 g (36 %) colorless crystals, m.p. 207-209 °C

Step E: Preparation of tert.-butyl (8-(4-cyanobenzoyl)-1-phenylmethyl-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl)acetate


20

136



0.9 g (2.3 mmol) of the compound from the previous Step were dissolved in 30 ml dry THF. After addition of 55 mg (2.3
 5 mmol) sodium hydride it was stirred for 30 min at room temperature followed by addition of 0.585 g (3.0 mmol) tert.-butyl bromoacetate. The mixture was stirred for two days and poured into ice water. It was extracted two times with ethyl acetate. The combined organic layers were dried over sodium
 10 sulfate and concentrated in vacuo, and the title hydantion was obtained by chromatography on silica gel with dichloromethane / ethanol 96:4.
 yield: 1.12 g (96 %) oil

15 Step F: Preparation of tert.-butyl (8-(4-((tert.-butoxycarbonylamino)iminomethyl)benzoyl)-1-phenylmethyl-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl)acetate



0.5 g (1.0 mmol) of the nitrile from Step E were dissolved in a mixture of 15 ml dry pyridine and 1.6 ml dry triethylamine. It was saturated with gaseous hydrogen sulfide, left at room temperature overnight, and poured into water. After three extractions with ethyl acetate the combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. The residue was dissolved in 100 ml toluene, which was distilled off again in vacuo to remove traces of pyridine. To the remaining substance were added 5 ml acetone and 5 ml methyl iodide, and it was heated with reflux for 45 min, while a crystalline precipitate was formed. It was concentrated under reduced pressure, dissolved in 4 ml dry methanol, treated with 0.3 g (3.9 mmol) ammonium acetate and heated for 2 h at 60 °C. The solvent was removed in vacuo, and the residue was stirred with ether. The solution was separated from the insoluble amidine, which was Boc-protected by dissolving in 10 ml of a 1:1 mixture of water and THF followed by addition of 0.9 g (6.5 mmol) potassium carbonate and 1.0 g (4.6 mmol) Boc2O and stirring for 1 hour at room temperature. It was diluted with water and extracted with ethyl acetate. The organic layer was dried over sodium sulfate and concentrated under reduced pressure, and the title compound was isolated by chromatography on silica gel with dichloromethane / ethanol 96:4.

yield: 0.24 g (39 %) oil

Step G: Preparation of (8-(4-(aminoiminomethyl)benzoyl)-1-phenylmethyl-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl)acetic acid trifluoroacetate


220 mg (0.355 mmol) of the protected amidine from the previous Step were stirred at room temperature with 2 ml trifluoroacetic acid. After 2 hours the solvent was removed in vacuo, and the residue was dissolved in water. Again it was concentrated under reduced pressure. The title acid

slowly precipitated by stirring with a mixture of ether and ethanol. It was collected by filtration and dried in vacuo.
yield: 0.05 g (24 %) colorless powder, m.p. > 197 °C (dec.)

5 ELISA: not tested PRP (ADP): IC₅₀ > 100 μM


Example 14

- 10 Preparation of
Ethyl 3-(3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl)propanoate Hydrochloride



15

Step A: Preparation of methyl (3-(4-cyanophenyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl)propanoate



20

To a suspension of 2.0 g (8.3 mmol) of the intermediate from Example 5, Step B in 30 ml dry ethanol were added 0.715 g (8.3 mmol) methyl acrylate. The mixture was stirred over

night at room temperature followed by 9 hours at 50 °C. It was diluted with water and extracted five times with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure. One crop
5 (0.64 g) of the title compound was obtained after chromatography on silica gel with ethyl acetate / ethanol 9:1 followed by recrystallization from ethanol. Another crop (0.23 g) was obtained by concentration of the aqueous layer to a small volume, filtration of the precipitate, stirring in
10 hot ethanol, another filtration, and drying in vacuo.
total yield: 0.87 g (32 %) colorless crystals, m.p. > 225 °C (dec.)

Step B: Preparation of ethyl 3-(3-(4-
15 (aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)propanoate hydrochloride

A solution of 0.39 g (1.19 mmol) of the nitrile from Step A in 30 ml dry ethanol was saturated with gaseous hydrogen
20 chloride followed by treatment with 40 ml saturated ethanolic ammonia solution according to the procedure from Example 5, Step D. The title amidine was obtained by chromatography on silica gel with dichloromethane / methanol 3:1.
yield: 0.23 g (49 %), pale yellow crystals, m.p. > 192 °C
25 (dec.)

ELISA: not tested

PRP (ADP):

IC₅₀ = 0.64 μM

30


Example 15

Preparation of

4-(3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)propanoic Acid

35

140



0.26 g (0.66 mmol) of the ester from Example 14 were
 5 hydrolyzed in a mixture of 4 ml ethanol and 0.9 ml 2 N
 aqueous sodium hydroxide solution as described in Example 6.
 The title acid crystallized from 1.5 ml ethanol / water 2:1.
 yield: 0.1 g (46 %) white powder, m.p. > 243 °C
 (dec.)


10

ELISA: not tested PRP (ADP): IC₅₀ = 0.11 μM

15

Example 16


Preparation of
 Ethyl 5-(3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-
 spiro[4.5]dec-2-en-8-yl)-5-oxopentanoate Hydrochloride



. HCl

20

Step A: Preparation of 5-(3-(4-cyanophenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)-5-oxopentanoic acid



5

To a suspension of 1.5 g (6.22 mmol) of the intermediate from Example 5, Step B in 40 ml dry THF were added 0.71 g (6.22 mmol) glutaric anhydride and 76 mg 4-N,N-dimethylaminopyridine (DMAP). It was stirred for 1 h at room temperature followed by 2 h heating with reflux. The solvent was removed under reduced pressure, and the title compound was obtained by chromatography on silica gel with dichloromethane containing 4 % ethanol. It was recrystallized from ethyl acetate / ether, and the crystals were collected by filtration and dried in vacuo.

yield: 0.97 g (44 %) white powder, m.p. 183 -185 °C

Step B: Preparation of ethyl 5-(3-(4-(aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)-5-oxopentanoate hydrochloride

A suspension of 0.91 g (2.56 mmol) of the nitrile from the previous Step in 60 ml dry ethanol was saturated with gaseous hydrogen chloride followed by treatment with 58 ml of a saturated ethanolic ammonia solution according to the procedure from Example 5, Step D. The mixture was concentrated under reduced pressure. A precipitate was removed by filtration after treatment with dichloromethane / ethanol 4:1, and the pure title amidine was obtained by chromatography on silica gel using the same solvent.

yield: 0.49 g (44 %), pale yellow oil, which solidified upon standing

ELISA: not tested PRP (ADP): $IC_{50} = 0.2 \mu M$


5

Example 17

Preparation of

5-(3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl)-5-oxopentanoic Acid

10



0.34 g (0.78 mmol) of the ethyl ester from Example 16 were dissolved in 5 ml ethanol, and after addition of 1 ml 2 N aqueous sodium hydroxide solution the mixture was stirred over night. It was brought to pH 5 with diluted acetic acid, stirred for 30 min, and the title acid was filtered with suction, washed with water and ethanol, successively, and dried in vacuo at 50 °C.

15

20

yield: 0.28 g (97 %), colorless crystals, m.p. > 280 °C (dec.)


25

ELISA: not tested PRP (ADP): $IC_{50} = 0.084 \mu M$


Example 18

Preparation of

Ethyl 5-(3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)pentanoate Hydrochloride



Step A: Preparation of ethyl 5-(3-(4-cyanophenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-8-yl)pentanoate



To a suspension of 1.1 g (4.56 mmol) of the intermediate from Example 5, Step B in 20 ml dry ethanol were added 1.26 g (9.12 mmol) potassium carbonate. After 15 min stirring at room temperature 1.03 g (4.93 mmol) ethyl 5-bromopentanoate and a catalytic amount of potassium iodide were added. It was stirred over night at room temperature, and the reaction was brought to completion by addition of another 0.52 g (2.49 mmol) ethyl 5-bromopentanoate and heating with reflux for 3 h. The mixture was poured into water and extracted three times with ethyl acetate. The combined organic layers were washed with water, dried over sodium sulfate, and

concentrated under reduced pressure. The title compound was obtained by chromatography on silica gel with dichloromethane / ethanol 95:5 followed by 92:8.

yield: 0.57 g (34 %), yellow oil, which solidified upon
5 standing

Step B: Preparation of ethyl 5-(3-(4-(aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-spiro[4.5]dec-2-en-
10 8-yl)pentanoate hydrochloride

A solution of 0.55 g (1.49 mmol) of the nitrile from the previous step in 35 ml dry ethanol was saturated with gaseous hydrogen chloride and converted to the title amidine with 45
15 ml saturated ethanolic ammonia solution as described in Example 9, Step B. It was purified by chromatography on silica gel with dichloromethane / ethanol 4:1 followed by 3:1, and it solidified after addition of some drops of ethanolic ammonia.
20 yield: 0.51 g (81 %), pale yellow amorphous solid, m.p. 146 - 148 °C


ELISA: not tested

PRP (ADP): not tested

25

Example 19

Preparation of
5-(3-(4-(Aminoiminomethyl)phenyl)-1-oxa-2,8-diaza-
30 spiro[4.5]dec-2-en-8-yl)pentanoic Acid



To a solution of 0.4 g (0.946 mmol) of the ester from Example
5 18 in 6 ml ethanol were added 1.2 ml 2 N aqueous sodium
hydroxide solution. The mixture was stirred at room
temperature over night, and stirring was continued for
another 30 min after addition of another 0.2 ml sodium
hydroxide. It was brought to pH 5 with diluted acetic acid,
10 and the precipitate of the title compound was filtered with
suction. After stirring with a small amount of water for 30
min, it was filtered again, washed with water and with
ethanol, and dried in vacuo at 60 °C.
yield: 0.125 g (37 %) colorless amorphous
15 solid, m.p. 236 - 238 °C (dec.)


ELISA: not tested PRP (ADP): IC₅₀ = 0.45 µM

20


Example 20

Preparation of
(9-(2-(Pyridin-4-yl)ethyl)-3,9-diazaspiro[5.5]undec-3-
25 yl)acetic Acid Bistrifluoroacetate

146



Step A: Preparation of 1,5-dicyano-2,4-dioxo-9-phenylmethyl-3,9-diazaspiro[5.5]undecane




10 A mixture of 159.7 g (0.844 mol) N-benzylpiperidone and 191.0 g (1.689 mol) ethyl cyanoacetate was dissolved in a 12% ethanolic solution of ammonia, and it was kept in a refrigerator for 8 days, while the title compound precipitated from the solution. It was collected by
15 filtration, washed with ethanol and ether, successively, and suspended in 910 ml water. It was brought to pH 6 with 2N hydrochloric acid, stirred for 1 h, filtered again, washed with water, and dried in vacuo.
yield: 177.2 g (65 %) pale yellow crystals,
20 m.p. 179 - 181 °C

Step B: Preparation of (4-(hydroxycarbonylmethyl)-1-phenylmethyl piperidin-4-yl)acetic acid hydrochloride


25

147



88.9 g (275.8 mmol) of the intermediate from the previous
5 step were heated in 550 ml 18% hydrochloric acid for 24 h.
After addition of 100 ml conc. HCl heating was continued for
the same period. Solids were removed by filtration, and the
title diacid precipitated upon concentration of the filtrate
to 60 % of its volume under reduced pressure. It was filtered
10 with suction, washed with ethanol, and dried *in vacuo*.
yield: 46.0 g (51 %) white powder, m.p. 223 -
225 °C

15 Step C: Preparation of 9-phenylmethyl-3,9-
diazaspiro[5.5]undecan-2,4-dione



20 11.6 g (35.4 mmol) of the diacid from Step B and 3.0 g (50.0
mmol) urea were thoroughly mixed in a mortar, and it was
heated at 160 °C for 6 h. After 30 minutes no gas evolution
could be observed. It was cooled to room temperature and
25 stirred with ethanol. The solids were collected by
filtration, suspended in saturated aqueous sodium bicarbonate
solution, and stirred until gas evolution had ended. The
title compound was filtered with suction, washed with water,
and dried *in vacuo*.
30 yield: 6.05 g (63 %) colorless needles,
m.p. 209 - 210 °C

Step D: Preparation of 3-phenylmethyl-3,9-diazaspiro[5.5]undecane

5



10 Under an atmosphere of argon was added in small portions to a suspension of 8.4 g (221.3 mmol) LiAlH₄ in 200 ml dry THF a suspension of 16.9 g (62.1 mmol) of the intermediate from the previous step in the same volume of THF, while the temperature was kept between 0 °C and 10 °C. It was stirred
15 for 1 h at room temperature and heated with reflux for another 4 h. The mixture was cooled and quenched with water. Solids were removed by filtration through a pad of silica gel, washed with ethanol, and the filtrate was concentrated under reduced pressure. The residue was stirred with ether,
20 and it was filtered again. The pure title intermediate was obtained from the filtrate by evaporation of the solvent in vacuo.

yield: 11.7 g (77 %) pale yellow amorphous solid, m.p. 105 - 106 °C (dec.)

25

Step E: Preparation of tert.-butyl (9-phenylmethyl-3,9-diazaspiro[5.5]undec-3-yl)acetate

30




A mixture of 10.0 g (40.9 mmol) of the compound from the previous step, 8.55 g (43.83 mmol) tert.-butyl bromoacetate, and 6.2 g (44.9 mmol) dry potassium carbonate in 200 ml dry ethanol was heated with reflux for 3 h. After cooling to room temperature solids were removed by filtration and washed with ethanol. The filtrate was concentrated under reduced pressure, and the residue was stirred with tert.-butylmethylether. It was filtered again and washed with the same solvent. The filtrate was washed four times with water, dried over sodium sulfate, and concentrated in vacuo to leave the pure title compound.

yield: 9.37 g (64 %) yellow oil

15

Step F: Preparation of tert.-butyl (3,9-diazaspiro[5.5]undec-3-yl)acetate




20

To a solution of 9.3 g (25.9 mmol) of the compound from Step E in 400 ml dry ethanol were added 1.5 ml acetic acid and 0.7 g Pd(II) hydroxide. The mixture was filled into an autoclave and hydrogenated at 50 atm and 50 °C for 18 h. The solvent was removed under reduced pressure, and the residue was stirred with saturated aqueous sodium bicarbonate solution. It was extracted five times with 100 ml tert.-butylmethylether followed by three extractions with 100 ml dichloromethane. The extracts were dried over sodium sulfate and concentrated in vacuo, separately. The first extract contained a mixture of compounds, whereas the pure title intermediate was obtained from the following.

yield: 5.52 g (79 %) oil, which solidified
upon standing

- 5 Step G: Preparation of tert.-butyl (9-(2-(pyridin-4-yl)ethyl)-3,9-diazaspiro[5.5]undec-3-yl)acetate



10

A solution of 2.5 g (9.3 mmol) of the compound from Step F and 0.98 g (9.3 mmol) 4-vinylpyridine in 20 ml dry acetonitrile was heated with reflux over night. The solvent
15 was removed under reduced pressure, and the title compound was obtained from the residue by chromatography on aluminum oxide with dichloromethane followed by dichloromethane / ethanol 9:1.

yield: 2.49 g (72 %) brown resin

20

Step H: Preparation of (9-(2-(pyridin-4-yl)ethyl)-3,9-diazaspiro[5.5]undec-3-yl)acetic acid bistrifluoroacetate

25 0.1 g (0.268 mmol) of the ester from Step G in 2 ml trifluoroacetic acid were stirred at room temperature for 30 minutes. The solvent was removed under reduced pressure, and the remaining title compound was stirred with ether, collected by filtration, and dried *in vacuo*.

30 yield: 0.12 g (82 %) beige hygroscopic
crystalline solid


ELISA: not tested

PRP (ADP): IC₅₀ > 100 μM

Example 21


Preparation of

- 5 4-(8-(4-(Aminoiminomethyl)benzoyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]decan-3-yl)butanoic Acid Trifluoroacetate



10

Step A: Preparation of 1,3,8-triaza-spiro[4.5]decan-2,4-dione




15

To a solution of 14.6 g (48.1 mmol) benzyl 2,4-dioxo-1,3,8-triaza-spiro[4.5]decan-8-carboxylate (prepared from N-(benzyloxycarbonyl)piperidone by the method from J. Med. Chem. **1995**, 38, 3772) in 250 ml dry ethanol were added 500 mg 10 % Pd/C, and the mixture was filled into an autoclave. After stirring at 60 °C and 10 atm of hydrogen for 3 h no starting hydantoin could be detected by TLC. A precipitate

had been formed which was redissolved by addition of 100 ml acetic acid. The catalyst was removed by filtration and the solution was concentrated *in vacuo*. Aqueous sodium bicarbonate solution was added until the mixture became a clear solution, and the title compound precipitated in two

total yield: 8.1 g (99 %), white powder, m.p. 303 - 304 °C (dec.)


Step B: Preparation of 8-(4-cyanobenzoyl)-1,3,8-triaza-spiro[4.5]decan-2,4-dione



7.6 g (45.9 mmol) 4-cyanobenzoyl chloride were added to a cooled solution of 7.8 g (46.1 mmol) of the compound from the previous step in a mixture of 400 ml dry THF and 67 ml dry pyridine. After stirring over night at room temperature the mixture was poured into ice-cold water. It was extracted two times with ethyl acetate, and the combined organic layers were washed with diluted aqueous Cu(II) sulfate solution and with brine, successively. It was dried over sodium sulfate, and the title compound precipitated upon concentration under reduced pressure. It was collected by filtration and dried *in vacuo*.

yield: 4.9 g (36 %), yellow crystalline solid, m.p. 144 - 146 °C

Step C: Preparation of tert.-butyl 4-(8-(4-cyanobenzoyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl)butanoate




5

A mixture of 2.4 g (8.0 mmol) of the compound from Step B, 1.8 g (10.1 mmol) tert.-butyl 4-chlorobutanoate (prepared according to Chem. Ber. 1965, 98, 2312), 2.8 g (20.3 mmol) dry potassium carbonate, and a catalytic amount potassium iodide in 50 ml dry DMF was heated at 100 °C for 6 h until the conversion was complete. It was poured into ice-cold water, and the crude solid title compound was collected by filtration. It was redissolved in hot ethyl acetate and dried over sodium sulfate, which was removed by filtration. The title hydantoin crystallized from the filtrate by addition of hexane.

yield: 2.4 g (68 %), colorless crystals, m.p. 225 - 226°C (dec.)

Step D: Preparation of tert.-butyl 4-(8-(4-((tert.-butoxycarbonylamino)iminomethyl)benzoyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl)butanoate

25



A solution of 0.9 g (2.0 mmol) of the compound from Step C in a mixture of 13 ml dry pyridine and 1.8 ml triethylamine was
5 saturated with hydrogen sulfide during 2 h. After stirring over night at room temperature it was poured into water and extracted three times with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated under reduced pressure followed by solution in
10 100 ml toluene. The solvent was evaporated *in vacuo* again, in order to remove remaining traces of pyridine. The residue was dissolved in 5 ml acetone, treated with 5 ml iodomethane, and heated with reflux for 75 minutes. It was concentrated to dryness, dissolved in 5 ml methanol, treated with 0.3 g (3.9
15 mmol) ammonium acetate, and heated for 2 h at 60 °C. The solvent was removed *in vacuo*, and the solid residue was washed by stirring with ether, dissolved in 20 ml of a mixture of THF / water 1:1 followed by addition of 1.8 g (13.0 mmol) potassium carbonate and 2.0 g (9.2 mmol) Boc_2O .
20 After stirring over night at room temperature it was diluted with water, extracted with ethyl acetate, and the organic layer was dried over sodium sulfate and concentrated under reduced pressure. The title compound was obtained from the residue by chromatography on silica gel with dichloromethane
25 / ethanol 9:1.
yield: 0.41 g (36 %), white powder, m.p. 133 - 135°C (dec.)

Step E: Preparation of 4-(8-(4-(aminoiminomethyl)benzoyl)-2,4-dioxo-1,3,8-triaza-spiro[4.5]dec-3-yl)butanoic acid trifluoroacetate


5 0.19 g (0.34 mmol) of the protected amidine from the previous step were stirred in 1 ml trifluoroacetic acid at room temperature for 45 minutes. The mixture was concentrated to dryness under reduced pressure, and the residue of the title compound crystallized by stirring in a mixture of ether and
10 ethanol. It was filtered with suction and dried *in vacuo*.
yield: 0.14 g (80 %), white powder, m.p. 226°C (dec.)

ELISA: not tested PRP (ADP): IC₅₀ > 10 µM

15

Example 22

Ethyl (3-(2-(Pyridin-4-yl)ethyl)-3-azaspiro[5.5]undec-9-yl)acetate
20 yl)acetate



25

A solution of 0.48 g (2.0 mmol) of the intermediate from Example 1, Step C and 0.21 g (2.0 mmol) 4-vinylpyridine in 6 ml acetonitrile were heated at 80 °C over night. The solvent was removed under reduced pressure, and the remaining solid
30 title compound was purified by stirring several times with tert.-butylmethylether, filtered with suction, and dried *in vacuo*.

yield: 0.17 g (25 %), brown crystalline solid, m.p. 142°C

ELISA: not tested

PRP (ADP):


IC₅₀ > 100 µM

5

Example 23

(3-(2-(Pyridin-4-yl)ethyl)-3-azaspiro[5.5]undec-9-yl)acetic
Acid

10




- 15 To a solution of 0.05 g (0.145 mmol) of the ester from
Example 22 in 2 ml ethanol were added three drops of 2N
aqueous sodium hydroxide solution. The mixture was heated at
70 °C for 3 h and diluted with 10 ml water. It was washed two
times with dichloromethane, and the aqueous layer was
20 adjusted to pH 7 - 8 with hydrochloric acid. After another
extraction with dichloromethane the aqueous layer was
concentrated under reduced pressure and the residue stirred
with 20 ml of a mixture of ethanol / dichloromethane 9:1.
Solids were removed by filtration, and the filtrate was
25 concentrated in vacuo to leave the pure title acid.
yield: 0.2 g (44 %), pale yellow resin
ELISA: not tested PRP (ADP): IC₅₀ > 100 µM

30

Example 24

Ethyl (3-(2-(Piperidin-4-yl)ethyl)-3-azaspiro[5.5]undec-9-yl)acetate



0.17 g (0.5 mmol) of the compound from Example 22 were dissolved in 25 ml 90 % acetic acid followed by addition of 30 mg platinum(IV) oxide. The mixture was filled into an autoclave and hydrogenated for 4 h at room temperature and a pressure of 20 atm. The catalyst was removed by filtration and the solvent evaporated under reduced pressure. The residue was treated with water and neutralized with sodium carbonate followed by extraction with dichloromethane. The organic layer was dried over sodium sulfate and concentrated *in vacuo* to leave the pure title compound.


yield: 0.04 g (23 %), brown resin

ELISA: not tested PRP (ADP): IC₅₀ > 100 μM

Example 25

(3-(2-(Piperidin-4-yl)ethyl)-3-azaspiro[5.5]undec-9-yl)acetic Acid

158



0.35 g (1.0 mmol) of the compound from Example 24 were
 5 hydrolized in 15 ml ethanol containing 7 drops aqueous sodium
 hydroxide as described for Example 23. The title acid
 solidified upon stirring in dichloromethane. It was filtered
 and dried *in vacuo*.

yield = 0.03 g (9 %), beige crystalline solid, m.p. 263 - 265

10 °C

ELISA: not tested

PRP (ADP):


IC₅₀ > 10 μM

15

Example 26


(9-(2-(Pyridin-4-yl)ethyl)-2,4-dioxo-3,9-
 diazaspiro[5.5]undec-3-yl)acetic Acid Trifluoroacetate

20



F₃CCOOH


25 Step A: Preparation of tert.-butyl (9-phenylmethyl-2,4-
 dioxo-3,9-diazaspiro[5.5]undec-3-yl)acetate



5 To a suspension of 10.0 g (36.7 mmol) of the imid from
Example 20, Step C in 100 ml dry DMF were added in small
portions 0.9 g (37.5 mmol) sodium hydride, which had been
purified from mineral oil by washing with hexane, and the
mixture was stirred for 30 minutes at 50 °C. After addition
10 of 7.0 g (35.9 mmol) tert.-butyl bromoacetate it was stirred
at room temperature over night, poured into 300 ml water, and
extracted two times with tert.-butylmethylether. The combined
organic layers were dried over sodium sulfate, concentrated
in vacuo, and the title ester was obtained by chromatography
15 on silica gel with dichloromethane followed by
dichloromethane / ethanol 96:4.

yield: 13.5 g (97 %) oil, which solidified
upon standing

Step B: Preparation of tert.-butyl (2,4-dioxo-3,9-
20 diazaspiro[5.5]undec-3-yl)acetate




25

To a solution of 13.4 g (34.7 mmol) of the compound from Step
A in 500 ml ethanol were added 2 ml acetic acid and 0.9 g
Pd(II) hydroxide. The mixture was filled into an autoclave

and hydrogenated at 50 °C and 50 atm for 20 h. The solvent was removed in vacuo, and the residue was stirred with saturated aqueous sodium bicarbonate solution. It was extracted several times with tert.-butylmethylether, and the combined extracts were dried over sodium sulfate and concentrated under reduced pressure. The title compound was obtained by chromatography on silica gel with dichloromethane followed by dichloromethane / ethanol 7:3.

yield: 6.8 g (66 %) oil, which solidified upon standing

Step C: Preparation of tert.-butyl (9-(2-(pyridin-4-yl)ethyl)-2,4-dioxo-3,9-diazaspiro[5.5]undec-3-yl)acetate



A solution of 3.0 g (10.1 mmol) of the compound from the previous step and 1.05 g (10.0 mol) 4-vinylpyridine in 20 ml dry acetonitrile were heated with reflux for 6 h and stirred over night at room temperature. The solvent was removed under reduced pressure, and the title pyridine was obtained by chromatography on silica gel with dichloromethane followed by dichloromethane / ethanol 9:1.

yield: 2.25 g (56 %) beige resinous crystals

Step D: Preparation of (9-(2-(pyridin-4-yl)ethyl)-2,4-dioxo-3,9-diazaspiro[5.5]undec-3-yl)acetic acid trifluoroacetate

0.1 g (0.25 mmol) of the ester from Step C were stirred in 2 ml trifluoroacetic acid at room temperature for 30 minutes. The solvent was removed *in vacuo*, and the remaining title compound was purified by treating with ethanol and dichloromethane, successively, which was removed under reduced pressure.


yield: 0.11 g (96 %), beige resinous crystals

ELISA: not tested PRP (ADP): IC₅₀ > 100 μM

10

Example 27


15 (9-(2-(Piperidin-4-yl)ethyl)-3,9-diazaspiro[5.5]undec-3-yl)acetic Acid Tristrifluoroacetate



20

Step A: Preparation of tert.-butyl (9-(2-(piperidin-4-yl)ethyl)-3,9-diazaspiro[5.5]undec-3-yl)acetate

25



0.83 g (2.22 mmol) of the pyridine from Example 20, Step G were dissolved in 50 ml dry ethanol followed by addition of 0.13 ml acetic acid and 0.1 g platinum(IV) oxide. The mixture was filled into an autoclave and hydrogenated at 50 °C and 100 atm. After three days the same amounts of acetic acid and of the catalyst were added, but even after eight days the conversion was not complete. The solvent was removed under reduced pressure, and the residue was stirred with 5 % aqueous sodium carbonate solution. It was extracted with tert.-butylmethylether, and the organic layer was dried over sodium sulfate and concentrated in vacuo. The acetate of the title compound, which was neutralized by washing a dichloromethane solution with 2N aqueous sodium hydroxide, was obtained by chromatography on aluminum oxide with dichloromethane followed by dichloromethane / ethanol 7:3.
yield: 0.42 g (50 %) beige resin

Step B: Preparation of (9-(2-(piperidin-4-yl)ethyl)-3,9-diazaspiro[5.5]undec-3-yl)acetic acid tristrifluoroacetate


0.1 g (0.263 mmol) of the ester from Step A were cleaved with trifluoroacetic acid as described for Example 26, Step D.
yield: 0.14 g (80 %) beige amorphous solid

ELISA: not tested PRP (ADP): IC₅₀ = 100 µM

30 Example 28

(9-(2-(Piperidin-4-yl)ethyl)-2,4-dioxo-3,9-diazaspiro[5.5]undec-3-yl)acetic Acid Diacetate

163



To a solution of 0.5 g (1.25 mmol) of the compound from
5 Example 26, Step C in 40 ml 90 % acetic acid were added 100
mg PtO₂. The mixture was filled into an autoclave and
hydrogenated at 20 atm and room temperature for 22 h. The
solvent was removed under reduced pressure, and the residue
was stirred with ether. The insoluble title compound was
10 separated and dried in vacuo.

yield: 0.56 g (95 %) pale yellow resin


ELISA: not tested

PRP (ADP): not tested

15


Example 29

(S)-5-(9-(3-((Aminoiminomethyl)amino)-1-oxopropyl)-3,9-
20 diazaspiro[5.5]undecan-3-yl)-2-benzenesulfonylamino-5-
oxopentanoic Acid Hydrochloride




25

Step A: Preparation of (S)-2-aminopentanedioic acid 1-tert.-butyl ester



To a solution of 25.0 g (74.1 mmol) (S)-2-(benzyloxycarbonylamino)pentanedioic acid 1-tert.-butyl ester
10 (prepared according to Liebigs Ann. Chem. **1961**, **646**, 127) in 500 ml dry methanol were added 2.5 g 10 % Pd/C, and the mixture was stirred over night at room temperature under an atmosphere of hydrogen. The catalyst was removed by filtration through celite and the filtrate was concentrated
15 under reduced pressure. The remaining solid title compound was purified by stirring with a small amount of ethanol, filtered with suction, and dried in vacuo. Another crop (1.7 g) was obtained after concentration of the mother liquid and stirring of the residue with ethyl acetate.
20 total yield: 11.55 g (77 %), white powder, m.p. 114 - 116 °C

Step B: Preparation of (S)-2-(benzenesulfonylamino)pentanedioic acid 1-tert.-butyl ester




30

11.5 g (56.6 mmol) of the amino acid from the previous step were dissolved in a mixture of 710 ml water and 57 ml 1N aqueous sodium hydroxide solution, and the solution was cooled to 0 °C. 6.6 g (62.3 mmol) sodium carbonate were added

followed by dropwise addition of 11.0 g (62.3 mmol) benzenesulfonyl chloride. After 1 h at 0 °C stirring was continued over night at room temperature, while the pH of the mixture dropped from pH 10 to pH 7. It was extracted two times with ethyl acetate, and the aqueous layer was adjusted to pH 2 with 2N hydrochloric acid. The solution was extracted four times with ethyl acetate, and the combined organic layers were washed with brine and with water, successively, dried over sodium sulfate, and concentrated under reduced pressure to leave the pure title sulfonamide.

yield: 13.0 g (67 %) pale yellow sirup, which solidified immediately upon standing

15 Step C: Preparation of (S)-tert.-butyl 2-benzenesulfonylamino-5-oxo-5-(9-phenylmethyl-3,9-diazaspiro[5.5]undecan-3-yl)pentanoate




20

A solution of 6.82 g (19.86 mmol) of the intermediate from Step B in 20 ml dry THF containing 2.8 ml triethylamine was cooled to - 10 °C. 2.15 g (19.8 mmol) ethyl chloroformate were added dropwise, and the mixture was stirred for ten minutes, while a precipitate was formed spontaneously. A solution of 4.85 g (19.86 mmol) of the intermediate from Example 20, Step D in a mixture of 24 ml dry THF and 5.3 ml triethylamine was added quickly in small portions. It was warmed to room temperature, stirred over night, poured into

water, and extracted three times with ethyl acetate. The combined organic layers were washed with water, dried over sodium sulfate, and concentrated under reduced pressure, and the title compound was obtained by chromatography on silica gel with dichloromethane / ethanol 93:7.

5 yield: 3.9 g (34 %) colorless crystalline solid, m.p. 134 - 136 °C

10 Step D: Preparation of (S)-tert.-butyl 2-benzenesulfonylamino-5-(3,9-diazaspiro[5.5]undecan-3-yl)-5-oxopentanoate acetate



15


To 200 mg 10 % Pd/C were added 30 ml dry methanol and 6 drops acetic acid. A stream of hydrogen was passed through the mixture for 20 minutes, and 2.0 g (3.5 mmol) of the intermediate from the previous step were added. It was stirred at room temperature for four days followed by addition of another 100 mg of the catalyst and 6 drops acetic acid, and stirring was continued for an additional day. The catalyst was removed by filtration through celite, and the filtrate was concentrated under reduced pressure to leave the title compound, which was purified by crystallization from ethyl acetate.

20 yield: 1.15 g (61 %) white powder, m.p. 153 - 156 °C

30

Step E: Preparation of (S)-tert.-butyl 2-benzenesulfonylamino-5-(9-(3-benzyloxycarbonylamino-1-oxopropyl)-3,9-diazaspiro[5.5]undecan-3-yl)-5-oxopentanoate

5




The reaction was carried out as described in Step C. A solution of 0.51 g (2.3 mmol) 3-(benzyloxycarbonylamino)propionic acid in 3 ml THF and 0.65 ml triethylamine was treated with 0.25 g (2.3 mmol) ethyl chloroformate followed by a solution of 1.1 g (2.04 mmol) of the compound from the previous step in a mixture of 4 ml THF, 0.6 ml triethylamine, and 1 ml water. It was stirred for two days at room temperature, and the pure title intermediate was obtained after chromatography on silica gel with dichloromethane containing 4 % ethanol.

yield: 0.86 g (62 %) colorless crystals, m.p. 50 - 54 °C

Step F: Preparation of (S)-tert.-butyl 5-(9-(3-amino-1-oxopropyl)-3,9-diazaspiro[5.5]undecan-3-yl)-2-benzenesulfonylamino-5-oxopentanoate

168




To a solution of 0.74 g (1.08 mmol) of the compound from Step E in 10 ml ethanol were added 70 mg 10 % Pd/C. It was stirred over night at room temperature, while a slight stream of hydrogen passed through the mixture. The catalyst was removed by filtration through celite, and the filtrate was concentrated in vacuo to leave the pure title amine.
 yield: 0.56 g (94 %) pale yellow foam

10

Step G: Preparation of (S)-tert.-butyl 2-benzenesulfonylamino-5-(9-(3-(((tert.-butoxycarbonylamino)(tert.-butoxycarbonylimino)methyl)amino)-1-oxopropyl)-3,9-diazaspiro[5.5]undecan-3-yl)-5-oxopentanoate

15



To a suspension of 0.44 g (2.03 mmol) mercury(II) oxide in 25 ml dry dioxane were added successively 0.56 g (1.02 mmol) of the amine from the previous step and 0.28 g (1.05 mmol) N,N'-bis(tert.-butoxycarbonyl)thiourea (prepared according to Tetrahedron Lett. **1992**, 33, 5933), each dissolved in a small

20

amount of dioxane. After two days stirring at room temperature another 50 mg mercury(II) oxide were added and stirring was continued for the same time. It was filtered through a pad of celite, and the filtrate was concentrated under reduced pressure. The title compound was obtained from the residue by chromatography on silica gel with dichloromethane containing 4 % ethanol.
yield: 0.52 g (64 %) pale yellow film, which solidified upon standing

10

Step H: Preparation of (S)-5-(9-(3-((aminoiminomethyl)amino)-1-oxopropyl)-3,9-diazaspiro[5.5]undecan-3-yl)-2-benzenesulfonylamino-5-oxopentanoic acid hydrochloride

15

A stream of gaseous hydrogen chloride was passed for 40 minutes through a solution of 0.3 g (0.38 mmol) of the protected guanidine from the previous step in 15 ml dry dichloromethane at 0 °C, while a precipitate was formed. It was stirred for additional 2 h at room temperature, and the solvent was removed under reduced pressure. The solid residue of the title compound was stirred with ether, filtered with suction, washed with ether, and dried in vacuo at 50 °C.
yield: 206 mg (95 %) colorless crystalline solid, m.p. > 127 °C (dec.)

25

ELISA: not tested


PRP (ADP): IC₅₀ =

Example 30

30


Preparation of (8-(4-(Aminoiminomethyl)benzoyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetic Acid.

170



Step A: Preparation of t-Butyl 8-Benzyl-(2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetate.

5



A solution of 8-benzyl-2-oxo-1-oxa-3,8-diazo-spiro[4.5]decane (0.83 g, 3.89 mmol), prepared as described
 10 in J. Med. Chem, 24, 1320-1328(1981), and tetrahydrofuran (5 mL) was treated with sodium hydride (0.102 g of a 60% dispersion in oil, 4.28 mmol). The resulting mixture was heated to reflux. After one hour, the mixture was allowed to cool to room temperature. This solution was treated with t-
 15 butyl bromoacetate (0.7 mL, 4.28 mmol) by dropwise addition. After one hour, the resulting mixture was diluted with ethyl acetate (50 mL) and washed with water.


The organic phase was concentrated *in vacuo*. The residue was chromatographed on silica gel, eluting with

171

hexanes/ethyl acetate (1:1), to give the title compound as a solid.


Yield = 1.12 g (83%), m.p. 157-159° C., FDMS m/z = 360.

- 5 Step B: Preparation of t-Butyl (2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetate.



- 10 A mixture of the compound prepared in Example 30A (0.60g, 1.66 mmol), 10% palladium in carbon (0.5 g), ethylacetate (200 mL), and ethanol (20 mL) was stirred under a H₂ atmosphere. After four hours, the reaction mixture was filtered, and the filtrate was concentrated in vacuo.
- 15 Yield = 0.41 g, m.p. 76-85° C., FDMS m/z = 270.

Step C: Preparation of t-Butyl (8-(4-cyanobenzoyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetate.




A solution of the compound prepared in Example 30B (0.15g, 0.556 mmol), methylene chloride (2.0 mL), and pyridine (2.0 mL) was treated with 4-cyanobenzoyl chloride (0.103 g, 0.611 mmol). After two hours at room temperature, the mixture was diluted with ethyl acetate (50 mL). The resulting mixture was washed with water, and concentrated in vacuo. The residue was chromatographed on silica gel, eluting with ethyl acetate.

Yield = 0.18 g FDMS m/z = 400.3

10

Step D: Preparation of t-Butyl (8-(4-(N-t-Butoxycarbonyl-aminoiminomethyl)benzoyl)-2-oxo-1-oxa-3,8-diazaspiro[4.5]dec-3-yl)acetate.



15

A mixture of the compound prepared in Example 30C (0.179g, 0.45 mmol), pyridine (10 mL), and triethylamine (1 mL) was saturated with H₂S, then allowed to stand at room temperature. After 18 hours, this mixture was concentrated to dryness. The residue was suspended in a mixture of acetone (5.0 mL) and methyl iodide (5.0 mL). The resulting mixture was heated at reflux for 1 hour. The reaction solution was then allowed to cool to room temperature and concentrated to dryness. The residue was dissolved in methanol (5 mL), and treated with ammonium acetate (0.10 g, 1.35 mmol). The resulting solution was heated at 60° C for 2

hours. This material was concentrated to dryness. The residue was suspended in a mixture of tetrahydrofuran and water (10 mL, 1:1) and treated with potassium carbonate (0.37 g, 2.7 mmol) and di-tert-butyl dicarbonate (0.49 g, 2.2 mmol). The resulting mixture was stirred at room temperature for 2 hours, then diluted with ethyl acetate (100 mL). The resulting mixture was washed with water, then the organic phase was concentrated. The residue was purified by chromatography, eluting with tetrahydrofuran/chloroform (1:8) giving the title compound.

Yield = 0.175 g FDMS m/z = 517.

Step E: Preparation of (8-(4-(Aminoiminomethyl)benzoyl)-2-oxo-2-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetic Acid.

A mixture of the compound prepared as described in Example 30D (0.175 g, 0.33 mmol) and trifluoroacetic acid (10 mL) was maintained at room temperature for 1 hour, then concentrated to dryness. The residue was triturated with diethyl ether, and the solid collected by filtration.


Yield = 0.17 g FAB MS m/z = 361.

ELISA: IC_{50} = 29 μM

PRP (ADP): IC_{50} = 80 μM


Example 31

Preparation of (8-(2-(4-Aminoiminomethyl)acetyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetic Acid.



Step A: Preparation of *t*-Butyl (8-(2-(4-Cyanophenyl)-acetyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetate.

5



A mixture of the compound prepared as described in Example 30B (0.08 g, 0.29 mmol), 4-cyanophenylacetic acid (0.051 g, 0.322 mmol) and methylene chloride (2.0 mL) was treated with 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (0.087 g, 0.44 mmol), and dimethylaminopyridine (catalytic amount). Resulting mixture was stirred at room temperature for about 2 hours. The reaction mixture was diluted with

10


175

ethyl acetate and washed with water. The organic phase was concentrated and the residue purified by chromatography, eluting with ethyl acetate.

Yield = 0.11 g (85%) FABMS m/z = 414.

5

Step B: Preparation of *t*-Butyl (8-(2-(4-*N*-*t*-Butoxycarbonyl aminoiminomethyl)acetyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetate.



10

The compound was prepared using the procedure substantially as described in Example 30D.

FDMS m/z = 414.

15

Step C: Preparation of (8-(2-(4-Aminoiminomethyl)acetyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetic Acid.

Compound was deprotected with trifluoroacetic acid following the procedure substantially as described in Example 30E.


FABMS m/z = 488.

ELISA: IC_{50} = .074 μM PRP (ADP): IC_{50} = 1.11 μM


25

Example 32

- 5 Preparation of ((9-(2-(4-(Aminoiminomethyl)phenyl)acetyl)-2-oxo-1-oxa-3,9-diaza-spiro[5.5]dec-3-yl)acetic Acid.



- 10 Step A: Preparation of t-Butyl (9-Benzyl-2-oxo-1-oxa-3,9-diaza-spiro[5.5]undec-3-yl)acetate.




- 15 The title compound was prepared from spirocarbonate prepared as described in Eur. J. Med. Chem. Ther., 9, 416-423 (1974), using the procedure substantially as described in Example 30A.

177

m.m. 113-144° C. FDMS m/z = 374.

Step B: Preparation of *t*-Butyl (2-oxo-1-oxa-3,9-diaza-spiro[5.5]undec-3-yl)acetate.

5




A mixture of the compound prepared as described in Step A (0.53 g), 10% palladium on carbon (0.5 g) and ethenol (10 mL) were maintained under hydrogen for 2 hours. The reaction mixture was filtered, and the filtrated concentrate *in vacuo*. Recrystallization of the residue from hexane provided the title compound

m.p. 110-115° C. FDMS m/z - 284.

15

Step C: Preparation of *t*-Butyl ((9-(2-(4-cyanophenyl)-acetyl)-2-oxo-1-oxa-3,9-diaza-spiro[5.5]undec-3-yl)acetate.




20

The title compound was prepared using the procedure substantially as described in Example 31A.

FDMS m/z = 427.

- 5 Step D: Preparation of *t*-Butyl ((9-(2-(4-(*N*-*t*-Butoxycarbonylaminoiminomethyl)phenyl)acetyl)-2-oxo-1-oxa-3,9-diaza-spiro[5.5]undec-3-yl)acetate.



10

The title compound was prepared using the procedure substantially as described in Example 30D.

FDMS m/z = 545.

- 15 Step E: Preparation of ((9-(2-(4-(Aminoiminomethyl)phenyl)acetyl)-2-oxo-1-oxa-3,9-diaza-spiro[5.5]undec-3-yl)acetic Acid.

20 The title compound was prepared using the procedure substantially as described in Example 30E.

FABMS m/z = 389.

ELISA: IC_{50} = .20 μM


PRP (ADP):

IC_{50} = 2.13 μM


25

Example 33

Preparation of (9-(4-(Aminoiminomethyl)benzoyl)-2-oxo-1-oxa-
5 3,9-diaza-spiro[5.5]undec-3-yl)acetic Acid.




Step A: Preparation of *t*-Butyl (9-(4-cyanobenzoyl)-2-oxo-1-oxa-
10 oxa-3,9-diaza-spiro[5.5]undec-3-yl)acetate.



The title compound was prepared using the procedure
15 substantially as described in Example 30C.
FDMS m/z = 413.

180

Step B: Preparation of *t*-Butyl (9-(4-(*N*-*t*-Butoxy-carbonylaminoiminomethyl)benzoyl)-2-oxo-1-oxa-3,9-diazaspiro[5.5]undec-3-yl)acetate.



5

The title compound was prepared using the procedure substantially as described in Example 30D.
FDMS m/z = 531.

10

Step C: Preparation of (9-(4-(Aminoiminomethyl)benzoyl)-2-oxo-1-oxa-3,9-diazaspiro[5.5]undec-3-yl)acetic Acid.

The title compound was prepared using the procedure substantially as described in Example 30E.
FABMS m/z = 375.

ELISA: IC_{50} = 16.5 μM PRP (ADP): IC_{50} = 66 μM


20

Example 34

Preparation of (8-(4-(Aminoiminomethyl)benzyloxy)-2-oxo-1-oxa-3-aza-spiro[4.5]dec-3-yl)acetic Acid.


25

181



Step A: Preparation of 8-(ethylene ketyl)-2-oxo-1-oxa-3-aza-spiro[4.5]decane-3-yl).


5



A solution of 1,4-cyclohexanedione mono-ethylene ketal (10 g, 64 mmol) in anhydrous methelane chloride (65 mL) was
10 treated with trimethylsilyl cyanide (9.4 mL, 70.4 mmol), and 18-crown-6 (catalitic). The mixture was stirred at 0° C under nitrogen for 35 minutes, then diluted with 5 volumes of ethyl acetate. The organic phase was washed with saturated sodium bicarbonate solution, then the organic phase was concentrated
15 in vacuo. The residue was dissolved in tetrahydrofuran, and the resulting solution treated with lithium aluminun hydride. After 1 hour, the reaction mixture was worked-up using the Steinhardt procedure (Fieser & Fieser, **Reagents for Organic Synthesis**, volume 1, page 584). The filtrate was

concentrated in vacuo and the resulting oil dissolved in methanol (50 mL). This solution was treated with potassium carbonate (8.85 g, 64 mmol). After 1 hour at room temperature, the potassium carbonate was removed by
5 filtration, and the filtrate concentrated in vacuo. The residue was treated with diethyl carbonate (65 mL) and a catalytic amount of sodium hydride. The resulting solution was heated to 125° C and methanol collected by distillation. After all the methanol had been distilled, a few milliliters
10 of diethyl carbonate were collected by distillation, then the solution was allowed to cool to room temperature. After dilution with ethyl acetate (10 volumes), the organic phase was washed with water and concentrated. The title compound was recrystallized from ethyl acetate/hexane.
15 Yield = 5 g (37%) m.p. 182-184° C.

Step B: Preparation of *t*-Butyl 8-(ethylene ketal)-2-oxo-1-oxa-3-aza-spiro[4.5]dec-3-yl)acetate.



20


The compound prepared in Step A (2.0 g, 9.38 mmol) in tetrahydrofuran (25 mL) was treated with sodium hydride (60% dispersion in oil, 0.39 g, 10.3 mmol). After heating at
25 reflux for 1 hour, *t*-Butyl- α -bromoacetate (1.32 mL, 10.3 mmol) was added to the reaction mixture. After an additional 1 hour at reflux, the solution was allowed to cool to room temperature. This solution was diluted with ethyl acetate

(10 volumes), washed with water, and concentrated *in vacuo*. The title compound was recrystallized from ethyl acetate/hexane.

Yield = 2.8 g (91%) m.p. 144-146° C.

5

Step C: Preparation of *t*-Butyl 8-oxo-2-oxo-1-oxa-3-aza-spiro[4.5]dec-3-yl)acetate.



10

The compound from Step B (3.1 g, 9.47 mmol) in acetone/water (3:1) was treated with pyridinium tosylate. After heating at 65° C. for 16 hours, the reaction was diluted with ethyl acetate (10 volumes). The organic phase was washed with 10% sodium bicarbonate, then concentrated *in vacuo*. The title compound was recrystallized from ethyl acetate/hexane.


15

Yield = 2.1 g (78%) m.p. 126-129° C. FDMS *m/z* = 284.

20

Step D: Preparation of (8-(4-cyanobenzyloxy)-2-oxo-1-oxa-3-aza-spiro[4.5]dec-3-yl)acetate.

184



The compound from Step C (0.25 g, 0.882 mmol) in methanol was treated with sodium borohydride (.033 g, 0.882 mmol). After 2 hours under nitrogen atmosphere, the reaction mixture was concentrated in vacuo. The residue was diluted with tetrahydrofuran (2.5 mL), then treated with sodium hydride (60% dispersion in oil, .034 g, 0.882 mmol). After 1 hour at room temperature under nitrogen, this mixture was treated with bromo-p-tolunitrile (.173 g, 0.882 mmol). After an additional 72 hours, the reaction mixture was diluted with ethyl acetate. The organic phase was washed with water and concentrated in vacuo. The residue was purified by silica-gel chromatography, eluting with chloroform/methanol (9:1). Yield = 12 mg (3.3%)

Step E: Preparation of (8-(4-(Aminoiminomethyl)benzyloxy)-2-oxo-1-oxa-3-aza-spiro[4.5]dec-3-yl)acetic Acid.


The compound from Step D (.012 g, .03 mmol) was converted to the title compound using the procedure substantially as described in Examples 30D and 30E.
Yield = 6 mg (43%) FDMS m/z = 362.

ELISA: IC₅₀ = .35 μ M PRP (ADP): IC₅₀ = 1.29 μ M

Example 35

Preparation of (8-(2-(4-(Aminoiminomethyl)phenyl)acetamido)-2-oxo-1-oxa-3-aza-spiro[4.5]dec-3-yl)acetic Acid.


5



Step A: Preparation of *t*-Butyl (8-(2-(4-cyanophenyl)-acetamido)-2-oxo-1-oxa-3-aza-spiro[4.5]dec-3-yl)acetate.

10

186



The ketone prepared as described in Example 34C was converted to the title compound using the procedure substantially as described in Example 36A.
Yield = 56 mg (15%) FDMS m/z = 428.

Step B: Preparation of (8-(2-(4-(Aminoiminomethyl)phenyl)-acetamido)-2-oxo-1-oxa-3-aza-spiro[4.5]dec-3-yl)acetic Acid.

10

The compound of Step A was converted to the title compound using the procedure substantially as described in Example 36B.

Yield = 10 mg (15%) m.p. 193-196° C. FABMS m/z = 389.

15


ELISA: IC₅₀ = .19 μM PRP (ADP): IC₅₀ = .77 μM

20


Example 36

Preparation of (8-(4-(Aminoiminomethyl)benzamido)-2-oxo-1-oxa-3-aza-spiro[4.5]dec-3-yl)acetic Acid.

187



Step A: Preparation of *t*-Butyl (8-(4-cyanobenzamido)-2-oxo-
5 1-oxa-3-aza-spiro[4.5]dec-3-yl)acetate.



The ketone prepared as described in Example 34C (0.25 g,
10 0.882 mmol), ammonium acetate (0.68 g, 8.82 mmol), methanol
(1.5 mL), was treated with sodium cyanoborohydride (0.055 g,
0.882 mmol). The resulting mixture was stirred at room
temperature for 16 hours, then concentrated *in vacuo*. The
residue was dissolved in water, the pH adjusted to pH 10, and
15 the product extracted with ethyl acetate. The combined
organic extracts were concentrated *in vacuo*, and the residue

dissolved in methylene chloride/pyridine (2.5/1.5 mL). This solution was treated with a solution of 4-cyanobenzoyl chloride (.160 g, .97 mmol) in methylene chloride (1 mL). The resulting solution was stirred under nitrogen for about 1
5 hour, then diluted with ethyl acetane (10 volumes). The organic phase was washed with water and concentrated in vacuo. The title compound was purified by silica-gel chromatography, eluting with 1% methanol in chloroform. The product was recrystallized from ethyl acetate/hexane.
10 Yield = 105 mg (30%) m.p. 200-205° C. FDMS m/z = 414.


Step B: Preparation of (8-(4-(Aminoiminomethyl)benzamido)-2-oxo-1-oxa-3-aza-spiro[4.5]dec-3-yl)acetic Acid.

15 The product from Step A was converted to the title compound using the procedure substantially as described in Example 34E.
Yield = 30 mg (65%) m.p. 280-284° C. FDMS m/z = 375.


20 ELISA: IC₅₀ = .17 μ M PRP (ADP): IC₅₀ = .51 μ M

Example 37

25 Preparation of ((8-(4-N-benzyloxycarbonylamino)-1-oxobutyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetate.




30 Step A: Preparation of ((8-(4-N-benzyloxycarbonylamino)-1-oxobutyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetate.



The amine prepared as described in Example 30B was
5 reacted with 4-(*N*-benzyloxycarbonylamino)butyric-acid using
the procedure as described in Example 38A.
Yield = 169 mg (93%) FDMS *m/z* = 490.

Step B: Preparation of *t*-Butyl (8-(4-(di-*t*-butoxycarbonyl-
10 aminoiminomethyl)-1-oxobutyl)-2-oxo-1-oxa-3,8-diaza-spiro-
[4.5]dec-3-yl)acetate.



15 The title compound was prepared from the compound of
Step A using the procedures substantially as described in
Example 38B.
Yield = 160 mg (83%) FDMS *m/z* = 598.

20 Step C: Preparation of ((8-(4-*N*-benzyloxycarbonylamino)-1-
oxobutyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetate.

The title compound was prepared from the compound of
Step B using the procedure substantially as described in
25 Example 38C.
Yield = 90 mg (79%) FDMS *m/z* = 342.


ELISA: $IC_{50} = 19 \mu M$ PRP (ADP): $IC_{50} = 52 \mu M$

5

Example 38


Preparation of (8-(4-(Aminoiminomethyl)-1-oxopentyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetic Acid.

10



Step A: Preparation of *t*-Butyl (8-(5-(*N*-benzyloxycarbonylamino)-1-oxopentyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetate.


15



A solution of the amine prepared as described in Example 30B (0.100 g, 0.37 mmol), 5-(*N*-benzyloxycarbonylamino)-pentolic acid (0.103 g, 0.41 mmol), EDCI (.105 g, .55 mmol), HOBT (0.074 g, 0.55 mmol) 4-DMAP (catalytic) and methylene chloride (2 mL) was stirred at room temperature for 1 hour. This solution was then diluted with ethyl acetate (15 volumes). The resulting solution was washed with water and concentrated *in vacuo*. The residue was purified by silica-gel chromatography, eluting with chloroform/methanol (95:5). Yield = 160 mg (86%) FDMS $m/z = 504$.

Step B: Preparation of *t*-Butyl (8-(5-(di-*t*-Butoxycarbonyl-aminoiminomethyl)-1-oxopentyl)-2-oxo-1-oxa-3,8-diaza-spiro-[4.5]dec-3-yl)acetate.

5



The compound from Step A (0.15 g, .298 mmol) and 5% palladium on carbon in absolute ethanol (10 mL) was rapidly stirred under a hydrogen atmosphere for 1 hour. The catalyst was removed by filtration and the filtrate concentrated in vacuo. The residue was treated with bis-Boc-thiourea (0.082 g, 0.298 mmol), triethylamine (0.14 mL, 0.983 mmol) mercury (II) chloride (0.89 g, 0.328 mmol), and dimethylformamide (2mL). The resulting mixture was stirred at 0° C. for 1 1/2 hours, then at room temperature for 1 hour. This mixture was diluted with ethyl acetate (15 volumes). The resulting mixture was washed with water and concentrated in vacuo. The residue was purified by silica-gel chromatography, eluting with chloroform/methanol (97:7). Yield = 160 mg (88%) FDMS m/z = 612.

Step C: Preparation of (8-(4-(Aminoiminomethyl)-1-oxopentyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetic
25 Acid.

The compound from Step B (0.15 g, 0.245 mmol) was treated with trifluoroacetic acid (5 mL). After 1 hour at room temperature, the solution was concentrated in vacuo. 30 The residue was dissolved in water and lyophilized. Yield = 100 mg (88%) FABMS m/z = 356.


ELISA: $IC_{50} = 1.85 \mu M$

PRP (ADP):

 $IC_{50} = 7 \mu M$ Example 39


5

Preparation of (8-(6-(aminoiminomethyl)-1-oxohexyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetic Acid.



10

Step A: Preparation of *t*-Butyl (8-(6-(benzyloxycarbonylamino)-1-oxohexyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetate.



15


The title compound was prepared from the amine of (6-(*N*-benzyloxycarbonylamino)hexoic acid substantially as described in Example 38A.

20 Yield = 230 mg (73%) FDMS $m/z = 518$.

Step B: Preparation of *t*-Butyl (8-(6-(di-*t*-Butoxytoxy-carbonylaminoiminomethyl)-1-oxohexyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetate.

25

193



The compound was prepared from the compound of Step A using the procedure substantially as described in Example 5 38B.

Yield = 250 mg (98%) FDMS m/z = 626.

Step C: Preparation of (8-(6-(aminoiminomethyl)-1-oxohexyl)-2-oxo-1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)acetic Acid. 10

The compound was prepared from the compound of Step B using the procedure substantially as described in Example 38C.

15 Yield = 156 mg (85%), FABMS m/z = 370.

ELISA: IC_{50} = 2.7 μM PRP (ADP): IC_{50} = 12 μM

EXAMPLE 40

20


Preparation of 2-(tert-butoxycarbonyl)-2,9-diaza-spiro[5.5]undecane:



25 The synthesis of the 2,9-diaza-spiro[5.5]undecane template was accomplished by slightly modifying the procedure utilized for the preparation of the 3,9-diaza-spiro[5.5]undecane as described in US patent # 5,451,578.

Step A:

30



Commercially available 1-benzyl-3-piperidone hydrochloride hydrate (1.89 g) was dissolved in H₂O (10 mL) and then 1M NaOH (9 mL) was added. The solution was stirred at rt for 5 minutes. Extraction with CH₂Cl₂ (3 x 20 mL), drying with Na₂SO₄, and removal of solvent under vacuum afforded 1.52g of the neutralized material.

This material was then dissolved in ice cold EtOH (15 mL) which was saturated with NH₃. Then ethyl cyanoacetate (1.7 mL) was added via syringe. The resulting solution was let standing at 0°C overnight. Evaporation of the solvent gave 2.8g of a viscous syrup. This syrup was dissolved in H₂O (11 mL) containing concentrated H₂SO₄ (13 mL) and the resulting solution was gently refluxed for 3 days. Removal of most of the H₂O under vacuum was followed by azeotropic removal of the rest of the H₂O using EtOH (4 x 50 mL). The product was then dissolved in EtOH (50 mL) and refluxed overnight. Most of the EtOH was then evaporated. After cooling to 0°C, H₂O (25 mL) added, and then K₂CO₃ (19 g) was carefully added with vigorous stirring. The mixture was carefully diluted with H₂O (200 mL) and washed with CH₂Cl₂ (2 x 150 mL). After the organics were dried with Na₂SO₄, the solvent was evaporated to afford 2.01 g (69% yield) of the desired diester which was used without further purification.

MS(ES): (M + H)⁺=348


Step B:



The diester (1.93 g) was dissolved in THF (10 mL) and cooled to -40°C. A commercially available solution of LAH in Et₂O (1M, 8.9 mL) was then slowly added via syringe followed by stirring for 40 minutes as it warmed to rt. After the reaction was cooled to 0°C, sequential addition of H₂O (0.35 mL), 1M NaOH (0.7 mL) and H₂O (0.8 mL) followed. The suspension was stirred vigorously for 1 h at 0°C, diluted with Et₂O (20 mL), and filtered. After thorough rinsing of the solid with Et₂O (150 mL), the solvent was removed under vacuum to afford 1.38 g of the desired diol (94% yield) which was used without further purification.

MS(ES): (M + H)⁺=264

Step C:



A solution of the N-benzyl diol (1.3 g), di-*tert*-butyl dicarbonate (1.1 g), and 10%Pd(OH)₂/C (130 mg) in MeOH (35 mL) was stirred at 50 psi of H₂ overnight. The mixture was filtered through celite and rinsed thoroughly with MeOH. Evaporation of the solvent afforded 859 mg (64% yield) of the desired carbamate which was used without further purification.

MS(ES): (M + H)⁺=274

Step D:



5 The carbamate (825 mg) was dissolved in anhydrous CH_2Cl_2 (15 mL) under an argon atmosphere and cooled to -20°C . To this solution was added Et_2N (1.23 mL) and then methanesulfonyl chloride (0.51 mL). The solution was stirred for 1 h, then poured into ice cold 1M citric acid (40 mL). This mixture was washed with Et_2O (4 x 30 mL). The combined organic washes were then
10 extracted with saturated NaHCO_3 (1 x 30 mL), dried with MgSO_4 and evaporated to give 604 mg (47% yield) of the di-mesylate intermediate which was used without further purification.


MS(ES): $(\text{M} + \text{H})^+ = 430$

15 The di-mesylate (600 mg) was dissolved in MeOH (10 mL). Concentrated NH_4OH (5 mL) was added and the reaction vessel was sealed stirred at 55°C overnight. After cooling to 0°C , the solution was poured into ice cold 0.5M NaOH (40 mL). Washing with EtOAc (3 x 50 mL), drying the organics with K_2CO_3 and solvent evaporation afforded 210 mg of the desired spirocycle.


20 MS(ES): $(\text{M} + \text{H})^+ = 254$

EXAMPLE 41

25 Preparation of 4-((3-(4-aminoiminomethyl)benzoyl)-3,9-diaza-spiro[5.5]undec-9-yl)-4-oxobutanoic acid:



30 Step A: Preparation of 3-tert-butoxycarbonyl-9-(4-cyanobenzoyl)-3,9-diaza-spiro[5.5]undecane




35 The synthesis of the starting material, 3-tert-butoxycarbonyl-3,9-diaza-spiro[5.5]undecane, was accomplished as described in US patent # 5,451,578. This material (1.45 g) was dissolved in CH_2Cl_2 (25 mL) and cooled to 0°C under an argon atmosphere. To this solution was added triethylamine (1.67 mL) and 4-dimethylaminopyridine (70 mg) followed by 4-cyanobenzoyl chloride (1.04 g). The mixture was stirred overnight as it warmed to rt. It was cooled to 0°C , and
40 ice cold 1M HCl (30 mL) was carefully added. The resulting mixture was washed with EtOAc (3 x 30 mL). Then washing the EtOAc with saturated NaHCO_3 and

brine followed by drying with MgSO_4 and evaporation of the solvent under reduced pressure afforded the title compound (1.62 g, 74%) as a yellow foam. Chromatography on silica gel with hexanes/ethyl acetate (2:1) as eluant gave pure compound.

5 MS(ES): $(M + H)^+ = 384$.

Step B: Preparation of 4-(3-(4-cyanobenzoyl)-3,9-diaza-spiro[5.5]undec-9-yl)-4-oxobutanoic acid:



To the material obtained in step A (100 mg) was added 40% TFA in CH_2Cl_2 (2.5 mL) at rt. After stirring for 1/2 h, the solvent was evaporated. The resultant residue was dissolved in anhydrous CH_2Cl_2 (3 mL) under argon and cooled to 0°C . After adding triethylamine (0.13 mL), succinic anhydride (30 mg) in CH_2Cl_2 (1.4 mL) was added. Stirring was continued overnight as it warmed to rt. The solvent was then evaporated and the residue was partitioned between 1M HCl (15 mL) and EtOAc (4 x 15 mL). The combined organics were washed with brine (30 mL), dried with MgSO_4 , and evaporated to afford 73 mg (74% yield) of the desired acid.

20 MS(ES): $(M + H)^+ = 384$.

Step C: Preparation of the title compound:

25 H_2S gas was bubbled gently for 10 minutes into a pyridine (4 mL) solution of the cyano acid (70 mg) obtained in part B containing triethylamine (0.22 mL). After the resultant solution was stirred at rt overnight, argon was bubbled through the solution for 1/2 h to remove excess H_2S . This pyridine solution was poured into 1M HCl (50 mL) and then saturated with NaCl. This solution was then washed with EtOAc (6 x 20 mL). The combined EtOAc was dried over MgSO_4 and evaporated to give 73 mg of a yellow semi-solid.

The yellow semi-solid was suspended in acetone (10 mL) and then methyl iodide (3 mL) was added. After stirring overnight at rt the solvent was evaporated to give 103 mg of a yellow semi-solid.

35 This material was then dissolved in EtOH (15 mL) and then ammonium acetate (2 g) was added. The resultant solution was stirred at 60°C overnight. Evaporation of the solvent afforded crude product which was then purified using reversed phase high pressure liquid chromatography (RP-HPLC).

MS(ES): $(M + H)^+ = 401$

40 ELISA: $\text{IC}_{50} = 15 \mu\text{M}$.

PRP (ADP): $\text{IC}_{50} = 14 \mu\text{M}$.

EXAMPLE 42

45 Preparation of 5-((3-(4-aminoiminomethyl)benzoyl)-3,9-diaza-spiro[5.5]undec-9-yl)-5-oxopentanoic acid:



5 The title compound was prepared by substantially following the procedure in Example 40 except that glutaric anhydride was used in place of succinic anhydride in step B.

MS(ES): $(M + H)^+ = 415$


ELISA: $IC_{50} = 3.5 \mu M$.

PRP (ADP): $IC_{50} = 10 \mu M$.

10

EXAMPLE 43

Preparation of Ethyl (3-(4-Aminoiminomethyl)benzoyl)-2-aza-spiro[5.5]undec-9-yl)acetate hydrochloride:



15


Step A: Preparation of benzyl-9-oxo-2-aza-spiro[5.5]undec-7-ene-3-carboxylate



20


25 A solution of benzyl-3-formylpiperidine-1-carboxylate (1 mmol) and methylvinyl ketone (1.2 mmol) was dissolved in MeOH (1 mL) and H₂O (1 mL). To this added catalytic amount of KOH and the solution was refluxed for 1 hour. To this then added powdered molecular sieves and refluxed for another 1 h. The HPLC analysis showed the completion of the reaction. The molecular sieves are filtered and the filtrate was evaporated. The residue was dissolved in CH₂Cl₂ and washed with water, dried, filtered and evaporated to give the desired spirocyclic enone as a yellow oil in 60% yield.

30 **Step B: Preparation of benzyl -9-(ethoxycarbonyl)methylene)2-aza-spiro[5.5]undec-7-ene-3-carboxylate**




To the suspension of sodium hydride (3mmol) in THF (2 mL) at 0°C was added triethylphosphonoacetate and then stirred for 30 min at 0°C. A solution of spiro compound (1mmol) from previous step in THF (2 mL) , and the reaction was heated to 50°C for 8h. The mixture was poured into water and extracted with ethylacetate. The title compound was purified by flash chromatography on silica gel using ethylacetate/hexane to give the desired pure compound as a colorless oil (50%)

Step C: Preparation of ethyl(2-aza-spiro[5.5]undec-9-yl)acetate



The protected spiro compound from Step B was dissolved in 10 mL of ethanol, and to this added Pd(II) hydroxide on carbon. The reaction was carried at 50 psi H2 pressure for 18 h. The catalyst was removed by filtering through celite, and the filtrate concentrated to give oil in 70% yield.

Step D: Preparation of ethyl(3-(4-cyanobenzoyl)-2-aza-spiro[5.5]undec-9-yl)acetate




The 1 mmol of compound from previous step and triethylamine (3mmol) were dissolved in dry CH₂Cl₂. To this added 4-cyanobenzoyl chloride (1.1 mmol) and solution was stirred for 12 hours at room temperature. The solvent was evaporated and the residue treated with water and extracted the product with ethylacetate. The organic layer was washed with 10% HCl solution, dried, and solvent removed to afford crude product. The product was purified on reverse phase HPLC to afford desired material as a yellow oil (60%).


Step E: Preparation of ethyl(3-(4-(hydroxyiminomethyl)benzoyl)-2-aza-spiro[5.5]undec-9-yl)acetate hydrochloride

To a solution of nitrile (1 mmol) in ethanol (5 mL) was added hydroxylamine hydrochloride (2mmol) and triethylamine (2mmol). The reaction mixture was heated to 65°C and stirred for 3 hours. The solvent was evaporated and diluted with water and extracted the product with ethylacetate. The organic layer was dried, filtered and evaporated to afford hydroxyamidino compound as a white solid.

199




5 **Step F: Preparation of ethyl(3-(4-aminoiminomethyl)benzoyl)-2-aza-spiro[5.5]undec-9-yl)acetate.**



10 To a suspension of the product from Step E in HOAc was added 5% Pd/C (50% wet). The mixture was heated at 50°C using 45 psi H₂ for 18 hours. The catalyst was filtered and the solvent evaporated under reduced pressure. The crude residue from this step was taken to next step without further purification


15 **Step G: Preparation of (3-(4-aminoiminomethyl)benzoyl)-2-aza-spiro[5.5]undec-9-yl)acetic acid**



20 50 mg of the ester from step F was treated with LiOH (4 eq) in H₂O and THF. The solution was stirred overnight, HPLC analysis showed completion of the reaction. The solvent was evaporated and the residue was purified on reverse phase HPLC to afford the desired pdt as a white solid in 50% yield. ESMS: 358(MH⁺)

EXAMPLE 44

Preparation of (3-(4-(Aminomethyl)benzoyl) 3-aza-spiro[5.5]undec-9-yl)propionic acid



5

Step A Preparation of benzyl -9-(ethoxycarbonyl) ethylene)3-aza-spiro[5.5]undec-7-ene-3-carboxylate

10




The spiro ketone (1 mmol), synthesized from N-carbobenzyloxy-4-formylpiperidine following the same procedure as in Example 1 (Step A) in THF was added to THF solution of triethyl phosphonopropionate and sodium hydride. The reaction mixture was heated at 50°C for 8h, followed by addition of water and extracting the product with dichloromethane. The dichloromethane layer was dried, filtered, evaporated to give light yellow oil. This was purified by silica gel chromatography to give colorless oil as the desired product

15

20

Step B: Preparation of ethyl(3-aza-spiro[5.5]undec-9-yl)propionate




The protected spiro compound from Step A was dissolved in 10 mL of ethanol, and to this added Pd(II) hydroxide on carbon. The reaction was carried at 50 psi H₂ pressure for 18 h. The catalyst was removed by filtering through celite, and the filtrate concentrated to give oil.

25

Step C: Preparation of ethyl(3-(4-cyanobenzoyl)-3-aza-spiro[5.5]undec-9-yl)propionate

30

201



5 The 1 mmol of compound from previous step and triethylamine (3mmol) were dissolved in dry CH_2Cl_2 . To this added 4-cyanobenzoyl chloride (1.1 mmol) and solution was stirred for 12 hours at room temperature. The solvent was evaporated and the residue treated with water and extracted the product with ethylacetate. The organic layer was washed with 10% HCl solution, dried, and solvent removed to afford crude product. The product was purified on reverse phase HPLC as a yellow oil.

10

Step D: Preparation of ethyl(3-(4-(hydroxyiminomethyl)benzoyl)-3-aza-spiro[5.5]undec-9-yl)propionate hydrochloride


15 To a solution of nitrile (1mmol) in ethanol (5 mL) was added hydroxylamine hydrochloride (2mmol) and triethylamine (2mmol). The reaction mixture was heated to 65°C and stirred for 3 hours. The solvent was evaporated and diluted with water and extracted the product with ethylacetate. The organic layer was dried, filtered and evaporated to afford hydroxyamidino compound as a white solid.

20 **Step E: Preparation of ethyl(3-(4-aminoiminomethyl)benzoyl)-3-aza-spiro[5.5]undec-9-yl)propionate.**

To a suspension of the product from Step E in HOAc was added 5% Pd/C (50% wet). The mixture was heated at 50°C using 45 psi H_2 for 18 hours. The catalyst was filtered and the solvent evaporated under reduced pressure. The crude residue from this step was taken to next step without further purification

25


Step F: Preparation of (3-(4-aminoiminomethyl)benzoyl)-3-aza-spiro[5.5]undec-9-yl)propionic acid



30

35 50 mg of the ester from step F was treated with LiOH (4 eq) in H_2O and THF. The solution was stirred overnight, HPLC analysis showed completion of the reaction. The solvent was evaporated and the residue was purified on reverse phase HPLC to afford the desired pdt as a white solid.

Preparation of (3-(4-Aminoiminomethyl)benzoyl)-3-aza-spiro[5.5]undec-9-carbonyl)formic acid hydrochloride:



Step A Preparation of 3-{2[(3-Azaspiro[5.5]undecane-9-diethyl ester



1-Benzyl-4-piperidone was converted to the bismesylate as described in (see Patent No. 5,451,578 for detailed procedure). To a slurry of 60% NaH (3 mmol) in toluene (10 mL) under argon, was slowly added diethyl malonate (1.5 mmol). The mixture was cooled to 0°C and bis-mesylate (1 mmol) was added and the mixture heated to reflux for 18 h. The reaction was quenched into 10% citric acid and product extracted with dichloromethane. The crude residue was purified by flash chromatography to give the desired diester in 65% yield.


Step B. Preparation of 3-{2[(3-Azaspiro[5.5]undecane-9-carbonyl)formic acid



To a solution of diester (300 mg) in THF (5 mL) is added 1N LiOH (4 mL) and stirred the reaction for 3 days at room temperature. The pH was adjusted to 2.5 and product extracted with ethylacetate. This mixture was redissolved in THF and added 1N LiOH and the reaction was heated at 80°C overnight. The pH was again adjusted to 2 and the desired acid extracted with ethylacetate. The organic layer was dried, filtered and evaporated to give desired Boc-acid as white foam (200 mg, 80%).


Step C: Preparation of (3-(4-cyano)benzoyl)-3-aza-spiro[5.5]undec-9-carbonyl)formic acid hydrochloride

203



To a solution of the BOC-acid (150 mg) in CH_2Cl_2 (2 mL) at 0°C is added TFA (2 mL). The solution is stirred at 0°C for 2h. The solvent and excess TFA are evaporated to an oily residue, which was used as such for the acylation step. The acid (1 mmol) is dissolved in CH_2Cl_2 (5 mL), added triethylamine (2 mmol) followed by p-cyanobenzoyl chloride (1.05 mmol). The solution was stirred for 12 hours at room temperature. The solvent was evaporated and residue was suspended in water and extracted the product with ethyl acetate. The organic layer is dried, filtered and evaporated to give crude product. The desired acylated material was isolated as a pure material after silica gel chromatography in approximately 60% yield. ES-MS: 327 ($\text{M} + \text{H}^+$)

Step D: Preparation of (3-(4-Aminoiminomethyl)benzoyl)-3-azaspiro[5.5]undec-9-carboxylic acid hydrochloride



A solution The nitrile was dissolved in a mixture of pyridine and triethylamine, and this was saturated with hydrogen sulfide, left at room temperature overnight. Then poured into water and extracted with ethyl acetate. The ethyl acetate layer was concentrated and to this added acetone and methyl iodide followed by reflux for 2h. After that concentrated the precipitate, dissolved in ethanol, treated with ammonium acetate and heated for 2h at 60°C . The solvent was removed to give the amidine functionality.

The following assay methods are suitable for evaluating the compounds of the invention.

No. 1 - The ELISA IIb-IIIa Assay:

In the following assay, GPIIb-IIIa is prepared in purified form, by a method such as described by Fitzgerald,

L.A., et al., Anal Biochem (1985) 151:169-177, (the disclosure of which is incorporated herein by reference). GPIIb-IIIa is coated onto microtiter plates. The coated support is then contacted with fibrinogen and with the test material (e.g., compounds of Formula I) and incubated for a sufficient time to permit maximal binding of fibrinogen to the immobilized GPIIb-IIIa. Fibrinogen is typically provided at a concentration of about 5-50 nM and the test material can, if desired, be added at a series of dilution. Typical incubations are 2 to 4 hours at 25 °C, the time and temperature being interdependent.

After incubation, the solution containing the fibrinogen and test material is removed and the level of binding of fibrinogen measured by quantitating bound fibrinogen to GPIIb-IIIa. Any suitable means of detection may be used, but it is convenient to employ labeled fibrinogen, for example using biotinylated labels. Such methods are well known in the art.

20 A. Description of Assays--Plate Assays

Purified platelet GPIIb-IIIa receptor was prepared as described by Fitzgerald, L.A., et al., Anal Biochem (1985) 151:169-177 (1985). Vitronectin receptor was prepared as described by Smith, J.W., J. Biol Chem (1988) 263:18726-18731. After purification, the receptors were stored in 0.1% Triton X-100 at 0.1-1.0 mg/ml.

The receptors were coated to the wells of 96-well flat-bottom ELISA plates (Linbro EIA-Plus microtiter plate, Flow Laboratories) after diluting 1:200 with a solution of 20 mM Tris-HCl, 150 mM NaCl, 1 mM CaCl₂, pH 7.4, to reduce the Triton X-100 concentration to below its critical micellar concentration and adding an aliquot of 100 ul to each well. The wells were all allowed to incubate overnight at 4 °C, and then aspirated to dryness. Additional sites were blocked by the addition of bovine serum albumin (BSA) at 35 mg/ml in the above buffer for two hours at 30 °C to prevent nonspecific

binding. The wells were then washed once with binding buffer (50 mM Tris-HCl, 100 mM NaCl 2 mM CaCl₂, 1 mg/ml BSA).

The corresponding ligands (fibrinogen, von Willebrand Factor, or vitronectin) were conjugated to biotin using commercially available reagents and standard protocols. The labeled ligands were added to the receptor-coated wells at final concentration of 10 nM (100 ul/well) and incubated for 3 hours at 25 °C in the presence or absence of the test samples. After incubation, the wells are aspirated to dryness and bound ligand is quantitated.

The bound protein is detected by the addition of antibiotin antibody conjugated to alkaline phosphatase followed by addition of substrate (p-nitrophenyl phosphate), and determination of the optical density of each well at 405 nM. Decreased color development is observed in wells incubated with test samples which inhibit binding of ligand to receptor.

20 No. 2 - The Platelet Aggregation Assay

In addition to the ELISA IIB-IIIa assay previously described the Aggregation-Human PRP/ADP Assay is useful for evaluating therapeutic compounds.

25 Platelet-rich plasma was prepared from healthy human volunteers for use in determining inhibition of platelet aggregation by the compounds. Blood was collected via a 21-gauge butterfly cannula, using a two-syringe technique into 1/10 volume of 3.8% trisodium citrate.

30 Platelet-rich plasma was prepared at room temperature by centrifugation of the citrated whole blood at 100 x g for twelve minutes. The platelet rich plasma contained approximately 200-400,000 platelets/ μ l.

35 Platelet-poor plasma was prepared by centrifugation of citrated whole blood at 12,000 x g for 2 minutes.

Platelet aggregation was assayed in a 4-channel platelet aggregation profiler (PAP-4, Biodata, Hatboro, PA)

according to the manufacturers directions. Inhibition of platelet aggregation was studied by adding varying amounts of adenosine diphosphate (ADP) to stirred human platelet-rich plasma. Specifically, the human platelet-rich plasma was
5 incubated with the compound being tested for 1 minute at 37 °C prior to the addition of a variety of aggregating agents most often ADP 5 μ M, but also 1 μ g/ml collagen, 1 μ M U46619 and
0.3 μ M platelet activating factor.

Pharmaceutical Compositions

Pharmaceutical formulations containing compounds of the invention can be administered orally in the form of tablets, capsules, solutions, emulsions or suspensions, inhaled liquid or solid particles, as a spray, through the skin by an appliance such a transdermal patch (such as described in US Patents No. 5,296,222 and 5,271,940, the disclosures of which are incorporated herein by reference) or rectally, for example, in the form of suppositories. The lipophilic prodrug derivatives of the invention are particularly well suited for transdermal absorption administration and delivery systems. Administration can also take place parenterally, for example in the form of injectable solutions.

Tablets are prepared by mixing the Active Ingredient ("Active Ingredient" is one or more spiro bicyclic compounds of the invention inclusive of those corresponding to formulae I) with pharmaceutically inert, inorganic or organic carriers, diluents, and/or excipients. Examples of such excipients which can be used for tablets, are lactose, maize starch or derivatives thereof, talc, stearic acid or salts thereof. Examples of suitable excipients for soft gelatin capsules are vegetable oils, waxes, fats, semisolid and liquid polyols.

Suitable excipients for the preparation of solutions and syrups are water, polyols, sucrose, invert sugar and glucose.

Suitable excipients for injectable solutions are water, alcohols, polyols, glycerol and vegetable oils.

These pharmaceutical products can additionally contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorings, buffers, coating agents and antioxidants.

Pharmaceutical compositions of this invention for parenteral injection comprise pharmaceutically-acceptable sterile aqueous or nonaqueous solutions, dispersions,

suspensions or emulsions as well as sterile powders for reconstitution into sterile injectable solutions or dispersions just prior to use.

The Active Ingredient can also be made in micro-encapsulated form.

Exemplary formulations using the Active Ingredient are described below:

Formulation 1

Hard gelatin capsules are prepared using the following ingredients:

	(mg/capsule)
Active Ingredient	250.0
Starch	305.0
Magnesium stearate	5.0

The above ingredients are mixed and filled into hard gelatin capsules in 560 mg quantities.

Formulation 2

A tablet formula is prepared using the ingredients below:

	(mg/tablet)
Active Ingredient	250.0
Cellulose, microcrystalline	400.0
Colloidal silicon dioxide	10.0
Stearic acid	5.0

The components are blended and compressed to form tablets, each weighing 665 mg.

Formulation 3

A dry powder inhaler formulation is prepared containing the following components:

5		<u>Weight %</u>
	Active ingredient	5
	Lactose	95

10 The active mixture is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.

Formulation 4

15 Tablets, each containing 60 mg of active ingredient, are prepared as follows:

		<u>(milligrams)</u>
	Active ingredient	60.0
	Starch	45.0
20	Microcrystalline cellulose	35.0
	Polyvinylpyrrolidone	
	(as 10% solution in water)	4.0
	Sodium carboxymethyl starch	4.5
	Magnesium stearate	0.5
25	Talc	1.0
	Total	150.0

 The active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixed thoroughly.

30 The solution of polyvinylpyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules as produced are dried at 50-60°C and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc,

35 previously passed through a No. 30 mesh U.S. sieve, are then added to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150mg.

Formulation 5

Capsules, each containing 80 mg of medicament are
5 made as follows:

	(milligrams)
Active ingredient	80.0
Starch	109.0
Magnesium stearate	1.0
10 Total	190.0

The active ingredient, cellulose, starch, and
magnesium stearate are blended passed through a No. 20 mesh
U.S. sieve, and filled into hard gelatin capsules in 190 mg
15 quantities.

Formulation 6

Suppositories, each containing 225 mg of active
20 ingredient are made as follows:

Active Ingredient	225 mg
Saturated fatty acid glycerides to	2000 mg

The active ingredient is passed through a No. 60
25 mesh U.S. sieve and suspended in the saturated fatty acid
glycerides previously melted using the minimum heat
necessary. The mixture is then poured into a suppository
mold of nominal 2.0 g capacity and allowed to cool.

30 Formulation 7

Suspensions, each containing 50 mg of medicament
per 5.0 mL dose are made as follows:

Active ingredient	50.0 mg
35 Xanthan gum	4.0 mg
Sodium carboxymethyl cellulose	(11%)
Microcrystalline cellulose	(89%) 50.0 mg

211

	Sucrose	1.75 g
	Sodium benzoate	10.0 mg
	Flavor	q.v.
	Color	q.v.
5	Purified water to	5.0mL

The medicament, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.

15 Formulation 8

Capsules, each containing 150 mg of medicament, are made as follows:

		(milligrams)
20	Active ingredient	150.0
	Starch	407.0
	Magnesium stearate	3.0
	Total	560.0

25 The active ingredient, cellulose, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 560 mg quantities.

30 Method of Treatment

This invention provides a method of preventing or treating thrombosis in mammals, especially humans, which method comprises administering to the human or mammal a therapeutically effective amount of the compounds of this invention. The platelet aggregation inhibitors of the invention are useful therapeutically to prevent thrombus

formation. Indications appropriate to such treatment include, without limitation, atherosclerosis and arteriosclerosis, acute myocardial infarction, chronic unstable angina, transient ischemic attacks and strokes, 5 peripheral vascular disease, arterial thrombosis, preeclampsia, embolism, restenosis and/or thrombosis following angioplasty, carotid endarterectomy, anastomosis of vascular grafts, and chronic cardiovascular devices (e.g., in-dwelling catheters or shunts "extracorporeal circulating 10 devices"). These syndromes represent a variety of stenotic and occlusive vascular disorders thought to be initiated by platelet activation on vessel walls.

The PAIs may be used for prevention or abortion of arterial thrombus formation, in unstable angina and arterial 15 emboli or thrombosis, as well as treatment or prevention of myocardial infarction (MI) and mural thrombus formation post MI. For brain-related disorders, treatment or prevention of transient ischemic attack and treatment of thrombotic stroke or stroke-in-evolution are included.

20 The PAIs may also be used for prevention of platelet aggregation, embolization, or consumption in extracorporeal circulations, including improving renal dialysis, cardiopulmonary bypasses, hemoperfusions, and plasmapheresis.

25 PAIs prevent platelet aggregation, embolization, or consumption associated with intravascular devices, and administration results in improved utility of intraaortic balloon pumps, ventricular assist devices, and arterial catheters.

30 The PAIs will also be useful in treatment or prevention of venous thrombosis as in deep venous thrombosis, IVC, renal vein or portal vein thrombosis, and pulmonary venous thrombosis.

Various disorders involving platelet consumption, 35 such as thrombotic thrombocytopenic purpura are also treatable.

In addition, the PAIs of the present invention may be used in numerous nontherapeutic applications where inhibiting platelet aggregation is desired. For example, improved platelet and whole blood storage can be obtained by adding sufficient quantities of the compounds, the amount of which will vary depending upon the length of proposed storage time, the conditions of storage, the ultimate use of the stored material, etc.

Preferably, the compounds of this invention are administered in the form of a pharmaceutical formulation. Thus, the compounds of this invention may be administered orally, parenterally, topically, rectally and etc., in, appropriate dosage units, as desired.

The term parenteral as used herein includes subcutaneous, intravenous, intraarterial, injection or infusion techniques, without limitation. The term, "topically" encompasses administration rectally and by inhalation spray, as well as the more common routes of the skin and the mucous membranes of the mouth and nose.

Actual dosage levels of active ingredients in the pharmaceutical compositions of this invention may be varied so as to administer an amount of the active compound(s) that is effective to achieve the desired therapeutic response for a particular patient.

The selected dosage level will depend upon the activity of the particular compound, the route of administration, the severity of the condition being treated, and the condition and prior medical history of the patient being treated. However, it is within the skill of the art to start doses of the compound at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved. If desired, the effective daily dose may be divided into multiple doses for purposes of administration, e.g., two to four separate doses per day. It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the body weight,

general health, diet, time and route of administration, combination with other drugs and the severity of the particular disease being treated.


5 The range of therapeutic dosages is from about 0.01 to about 10,000 milligrams per day, with from 1 to 300 milligrams being preferred.

10 Many modifications and variations of this invention may be made without departing from its scope, as is apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims.

CLAIMS:

5

1. A compound of formula (I):



10 wherein;

the atoms A_i and B_j are independently selected from carbon, nitrogen, oxygen or sulfur, provided that at least one atom of A_i is carbon, and at least one atom B_j is carbon;

the rings of the spirobicycle formed by A_i and B_j ,
 15 respectively, may optionally be partly unsaturated;

p and q are independently numbers from 2 to 6;

m is a number from zero to p ;

R_{10} is the same or different and is a non-interfering substituent independently selected from hydrogen,
 20 alkyl, halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl, arylalkyl, hydroxy, alkoxy, arylalkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, sulfo, =O, or =S, with the proviso that only one R_{10} may be =O or =S, if p is 2 or one or two R_{10} may be =O or =S,
 25 if p is a number from 3 to 6;

n is the number from zero to q ;

R_0 is the same or different and is a non-interfering substituent independently selected from hydrogen, alkyl,
 halosubstituted alkyl, alkenyl, alkynyl, cycloalkyl, aryl,
 30 arylalkyl, hydroxy, alkoxy, arylalkoxy, amino, substituted amino, carbamoyl, carboxy, acyl, cyano, halo, nitro, sulfo, =O, or =S, with the proviso that only one R_0 may be =O or =S,


if q is 2 or one or two R_0 may be $=O$ or $=S$, if q is a number from 3 to 6;

the linking group $-(L)-$ is a bond or a divalent substituted or unsubstituted chain of from 1 to 10 atoms selected from the group consisting of carbon, nitrogen, sulfur, and oxygen;

Q is a basic group containing one or more basic radicals; and

R_3 is an acidic group containing one or more acid radicals;
or a pharmaceutically-acceptable salt, solvate or or prodrug thereof

2. A spirocyclic compound of the formula





wherein:








Q is a basic group;

L is CO , $CO(C_1-C_6 \text{ alkyl})$, $O(C_1-C_6 \text{ alkyl})$, $NHCO$, or $C_1-C_6 \text{ alkyl}$;


Z is a spirocyclic group selected from







, or



where $Q-(L)_z$ is attached at a, and R_3 is attached at b;

- R_3 is CO_2R_5 , $(C_1-C_6 \text{ alkyl})CO_2R_5$, $CO(C_1-C_6$
 5 $\text{alkyl})CO_2R_5$, $CONH(C_1-C_6 \text{ alkyl})CO_2R_5$, $(C_1-C_6$
 $\text{alkyl})CH(NHR_4)CO_2R_5$, $CO(C_1-C_6 \text{ alkyl})CH(NHR_4)CO_2R_5$, or $CONH(C_1-$
 $C_6 \text{ alkyl})CH(NHR_4)CO_2R_5$;

R_2 is hydrogen, C_1-C_6 alkyl, aryl, substituted
 aryl, or arylalkyl;


- 10 R_4 is $SO_2(C_1-C_6\text{alkyl})$, SO_2 aryl, or SO_2 (substituted
 aryl);

R_5 is hydrogen, C_1-C_6 alkyl, aryl, or substituted
 aryl; and

z is 0 or 1, m is 1 or 2;

or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.

3. The compound of Claim 2 wherein Q is pyridin-4-yl, piperidin-4-yl, amidino, hydroxyamidino, guanidiny1, or a group of the formula:




10


wherein R_{20} is hydrogen or halogen.


4. The compound of Claim 3 wherein Z is a spirocyclic group selected from:

15




5. The compound of Claim 3 wherein Z is a spirocyclic group selected from:






where m is one or two, and R₂ is as defined in Claim 2.

6. The compound of Claim 3 wherein Z is a spirocyclic group
5 selected from:



where m is one or two, and R₂ is as defined in Claim 2.

7. The compound of Claim 3 wherein Z is a spirocyclic group selected from:



where m is one or two, and R₂ is as defined in Claim 2.

10

8. The compound of Claim 2 wherein R₃ is CO₂R₅, (C₁-C₆ alkyl)CO₂R₅, CO(C₁-C₆ alkyl)CO₂R₅, or CONH(C₁-C₆ alkyl)CO₂R₅.

9. The compound of Claim 2 wherein R₃ is (C₁-C₆ alkyl)CH(NHR₄)CO₂R₅, CO(C₁-C₆ alkyl)CH(NHR₄)CO₂R₅, or CONH(C₁-C₆ alkyl)CH(NHR₄)CO₂R₅.

15

10. The compound of Claim 2 wherein L is CO or NHCO, and z is one.



20

11. The compound of Claim 2 wherein z is zero.


12. The compound of Claim 3 wherein Q is a group of the formula:

25

224



or














wherein R_{20} is hydrogen or halogen.











13. The compound of Claim 8 wherein R_5 is hydrogen.



5


14. The compound of Claim 2 selected from the group consisting of:

































232



wherein X is F or H, m is zero to four, and n is one to four, or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.

- 5 15. The compound of Claim 2 selected from the group consisting of:















5 wherein X is F or H, m is zero to four, and n is one to
 four, or a pharmaceutically-acceptable salt, solvate, or
 prodrug thereof.


16. The compound of Claim 2 selected from the group
 10 consisting of:

235













239






wherein X is F or H, or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.

17. The compound of Claim 2 selected from the group
5 consisting of:



10






wherein X is F or H, or a pharmaceutically-acceptable
 5 salt, solvate, or prodrug thereof.


18. The compound of Claim 2 selected from the group
 consisting of:

243





wherein X is F or H, m is zero to four, and n is one to
 four, or a pharmaceutically-acceptable salt, solvate, or
 5 prodrug thereof.

19. The compound of Claim 2 selected from the group
 consisting of:




245



5 wherein X is F or H, or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.

20. The compound of Claim 2 having the formula:




10

 wherein X is F or H and m is zero to four, or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.

15 21. The compound of Claim 2 having the formula:


246



wherein X is F or H and n is one to four, or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.

5


22. The compound of Claim 2 having the formula:



wherein X is F or H and n is one to four, or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.

10


23. The compound of Claim 2 having the formula:



15


wherein X is F or H and m is zero to four, or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.

- 5 24. The compound of Claim 2 having the formula:



- 10 wherein X is F or H and n is one to four, or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.


25. The compound of Claim 2 having the formula:



- 15 or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.


26. The compound of Claim 2 having the formula:

248



wherein X is F or H, or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.

- 5 27. The compound of Claim 2 having the formula:



or a pharmaceutically-acceptable salt, solvate, or prodrug thereof.

10

28. A composition for inhibiting the binding of fibrinogen to blood platelets in a mammal, comprising a compound of any one of Claims 1 to 27 and a pharmaceutically-acceptable carrier.

15

29. A composition for inhibiting the aggregation of blood platelets in a mammal, comprising a compound of any one of Claims 1 to 27 and a pharmaceutically-acceptable carrier.

5 30. A composition for preventing or treating thrombosis in a mammal, comprising a compound of any one of Claims 1 to 27 and a pharmaceutically-acceptable carrier.

10 31. A method for inhibiting the binding of fibrinogen to blood platelets in a mammal, which comprises administering to the mammal a composition of Claim 28.

15 32. A method for inhibiting the aggregation of blood platelets in a mammal, which comprises administering to the mammal a composition of Claim 29.

20 33. A method for preventing or treating thrombosis in a mammal, which comprises administering to the mammal a composition of Claim 30.

25 34. A composition for treating a mammal, including man, to alleviate the pathological effects of atherosclerosis, arteriosclerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism, restenosis following angioplasty, carotid endarterectomy, and anastomosis of vascular grafts, comprising a compound of any one of Claims 1 to 27 and a pharmaceutically-acceptable carrier.

30 35. A method of treating a mammal, including man, to alleviate the pathological effects of atherosclerosis, arteriosclerosis, acute myocardial infarction, chronic stable angina, unstable angina, transient ischemic attacks and strokes, peripheral vascular disease, arterial thrombosis, preeclampsia, embolism, restenosis following angioplasty,

carotid endarterectomy, and anastomosis of vascular grafts;
wherein the method comprises administering to said mammal at
least one compound as claimed in any one of Claims 1 to 27;
wherein, said compound is administered to said mammal in an
5 amount sufficient to inhibit binding of fibrinogen on
glycoprotein IIb-IIIa sites in said mammal to thereby
alleviate said effects.

36. A pharmaceutical formulation containing as an active
10 ingredient a compound as claimed in any one of Claims 1 to
27, associated with one or more pharmaceutically-acceptable
carriers therefor.

37. The use of a compound as claimed in any one of Claims 1
15 to 27 for the manufacture of a medicament for the treatment
of atherosclerosis, arteriosclerosis, acute myocardial
infarction, chronic stable angina, unstable angina, transient
ischemic attacks and strokes, peripheral vascular disease,
arterial thrombosis, preeclampsia, embolism, restenosis
20 following angioplasty, carotid endarterectomy, and
anastomosis of vascular grafts.

38. The use of a compound as claimed in any one of Claims 1
to 27 for the manufacture of a medicament for the treatment
25 of thrombosis.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/15703

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C07D221/20 A61K31/435 C07D498/10 C07D471/10 C07D401/06 C07D263/52 A61K31/42 //(C07D498/10,263:00,221:00), (C07D498/10,261:00,221:00),(C07D498/10,265:00,221:00), According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 6 C07D A61K Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used)																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="width: 10%;">Category *</th> <th style="width: 70%;">Citation of document, with indication, where appropriate, of the relevant passages</th> <th style="width: 20%;">Relevant to claim No.</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">X</td> <td>WO 95 14683 A (DU PONT MERCK) 1 June 1995 see page 249 - page 252; claims 16,31; table 3 ---</td> <td style="text-align: center;">1,28</td> </tr> <tr> <td style="text-align: center;">A</td> <td>US 5 451 578 A (CLAREMON) 19 September 1995 see claims 1,8 ---</td> <td style="text-align: center;">1,28</td> </tr> <tr> <td style="text-align: center;">A</td> <td>EP 0 635 492 A (ELI LILLY) 25 January 1995 see page 2, line 8 - line 17; claim 1 ---</td> <td style="text-align: center;">1,28</td> </tr> <tr> <td style="text-align: center;">A</td> <td>EP 0 655 439 A (ELI LILLY) 31 May 1995 see claims 1,10 ---</td> <td style="text-align: center;">1,28</td> </tr> <tr> <td style="text-align: center;">P,X</td> <td>WO 96 38426 A (DU PONT MERCK) 5 December 1996 see table 3, pages 222-225 and table 8, pages 255-256; and page 1, lines 9 - 18 -----</td> <td style="text-align: center;">1,28</td> </tr> </tbody> </table>			Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.	X	WO 95 14683 A (DU PONT MERCK) 1 June 1995 see page 249 - page 252; claims 16,31; table 3 ---	1,28	A	US 5 451 578 A (CLAREMON) 19 September 1995 see claims 1,8 ---	1,28	A	EP 0 635 492 A (ELI LILLY) 25 January 1995 see page 2, line 8 - line 17; claim 1 ---	1,28	A	EP 0 655 439 A (ELI LILLY) 31 May 1995 see claims 1,10 ---	1,28	P,X	WO 96 38426 A (DU PONT MERCK) 5 December 1996 see table 3, pages 222-225 and table 8, pages 255-256; and page 1, lines 9 - 18 -----	1,28
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
X	WO 95 14683 A (DU PONT MERCK) 1 June 1995 see page 249 - page 252; claims 16,31; table 3 ---	1,28																		
A	US 5 451 578 A (CLAREMON) 19 September 1995 see claims 1,8 ---	1,28																		
A	EP 0 635 492 A (ELI LILLY) 25 January 1995 see page 2, line 8 - line 17; claim 1 ---	1,28																		
A	EP 0 655 439 A (ELI LILLY) 31 May 1995 see claims 1,10 ---	1,28																		
P,X	WO 96 38426 A (DU PONT MERCK) 5 December 1996 see table 3, pages 222-225 and table 8, pages 255-256; and page 1, lines 9 - 18 -----	1,28																		
<input type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.																				
<table style="width: 100%;"> <tr> <td style="width: 50%; vertical-align: top;"> * Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed </td> <td style="width: 50%; vertical-align: top;"> *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *&* document member of the same patent family </td> </tr> </table>			* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *&* document member of the same patent family																
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art *&* document member of the same patent family																			
Date of the actual completion of the international search <div style="text-align: center; font-weight: bold;">21 January 1997</div>		Date of mailing of the international search report <div style="text-align: center; font-weight: bold;">31. 01. 97</div>																		
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl, Fax (+ 31-70) 340-3016		Authorized officer <div style="text-align: center; font-weight: bold;">Alfaro Faus, I</div>																		

INTERNATIONAL SEARCH REPORT

Int'l Application No.

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 6 (C07D471/10,235:00,221:00), (C07D471/10,221:00,221:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.

☐ Further documents are listed in the continuation of box C.

☐ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

Name and mailing address of the ISA
 European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax (+31-70) 340-3016

Authorized officer

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 96/ 15703

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 31-33 and 35 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/ composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
On grounds of Articles 6 and 17.2a(11) of the PCT (conciseness of claims) and the Guidelines for Examination in the EPO, Part B, Chapter III, 2.2 (economic reasons) the search has been restricted to the preparation examples in the description.
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

Int'l Application No

PCT/US 96/15703

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9514683	01-06-95	AU-A- 1098095 CA-A- 2174838 EP-A- 0730590 FI-A- 962184 NO-A- 962096 PL-A- 314591 ZA-A- 9409337	13-06-95 01-06-95 11-09-96 23-05-96 23-05-96 16-09-96 24-05-96
US-A-5451578	19-09-95	GB-A- 2292147	14-02-96
EP-A-635492	25-01-95	AU-A- 6750094 BR-A- 9402916 CA-A- 2128348 CN-A- 1108248 CZ-A- 9401740 FI-A- 943478 HU-A- 70397 JP-A- 8188564 NO-A- 942734 PL-A- 304388 ZA-A- 9405251	02-02-95 11-04-95 23-01-95 13-09-95 13-09-95 23-01-95 30-10-95 23-07-96 23-01-95 23-01-95 18-01-96
EP-A-655439	31-05-95	CA-A- 2134192 JP-A- 7188165	13-05-95 25-07-95
WO-A-9638426	05-12-96	NONE	